Identification	O
of	O
a	O
region	O
which	O
directs	O
the	O
monocytic	O
activity	O
of	O
the	O
colony-stimulating	B-DNA
factor	I-DNA
1	I-DNA
(	I-DNA
macrophage	I-DNA
colony-stimulating	I-DNA
factor	I-DNA
)	I-DNA
receptor	I-DNA
promoter	I-DNA
and	O
binds	O
PEBP2/CBF	B-protein
(	O
AML1	B-protein
)	O
.	O

The	O
receptor	O
for	O
the	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
or	O
colony-stimulating	B-protein
factor	I-protein
1	I-protein
[	O
CSF-1	B-protein
]	O
)	O
is	O
expressed	O
from	O
different	O
promoters	O
in	O
monocytic	B-cell_type
cells	I-cell_type
and	O
placental	B-cell_type
trophoblasts	I-cell_type
.	O

We	O
have	O
demonstrated	O
that	O
the	O
monocyte-specific	O
expression	O
of	O
the	O
CSF-1	B-protein
receptor	I-protein
is	O
regulated	O
at	O
the	O
level	O
of	O
transcription	O
by	O
a	O
tissue-specific	B-DNA
promoter	I-DNA
whose	O
activity	O
is	O
stimulated	O
by	O
the	O
monocyte/B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
PU.1	B-protein
(	O
D.-E.Zhang	O
,	O
C.J.Hetherington	O
,	O
H.-M.Chen	O
,	O
and	O
D.G.Tenen	O
,	O
Mol.Cell.	O
Biol.14	O
:	O
373-381	O
,	O
1994	O
)	O
.	O

Here	O
we	O
report	O
that	O
the	O
tissue	O
specificity	O
of	O
this	O
promoter	B-DNA
is	O
also	O
mediated	O
by	O
sequences	O
in	O
a	O
region	B-DNA
II	I-DNA
(	O
bp	O
-88	O
to	O
-	O
59	O
)	O
,	O
which	O
lies	O
10	B-DNA
bp	I-DNA
upstream	I-DNA
from	O
the	O
PU.1-binding	B-DNA
site	I-DNA
.	O

When	O
analyzed	O
by	O
DNase	B-protein
footprinting	O
,	O
region	B-DNA
II	I-DNA
was	O
protected	O
preferentially	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
confirmed	O
that	O
region	B-DNA
II	I-DNA
interacts	O
specifically	O
with	O
nuclear	B-protein
proteins	I-protein
from	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Two	O
gel	B-protein
shift	I-protein
complexes	I-protein
(	O
Mono	B-protein
A	I-protein
and	O
Mono	B-protein
B	I-protein
)	O
were	O
formed	O
with	O
separate	O
sequence	O
elements	O
within	O
this	O
region	O
.	O

Competition	O
and	O
supershift	O
experiments	O
indicate	O
that	O
Mono	B-protein
B	I-protein
contains	O
a	O
member	O
of	O
the	O
polyomavirus	B-protein
enhancer-binding	I-protein
protein	I-protein
2/core-binding	I-protein
factor	I-protein
(	I-protein
PEBP2/CBF	I-protein
)	I-protein
family	I-protein
,	I-protein
which	O
includes	O
the	O
AML1	O
gene	O
product	O
,	O
while	O
Mono	B-protein
A	I-protein
is	O
a	O
distinct	O
complex	O
preferentially	O
expressed	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Promoter	B-DNA
constructs	I-DNA
with	O
mutations	O
in	O
these	O
sequence	O
elements	O
were	O
no	O
longer	O
expressed	O
specifically	O
in	O
monocytes	B-cell_type
.	O

Furthermore	O
,	O
multimerized	B-DNA
region	I-DNA
II	I-DNA
sequence	I-DNA
elements	I-DNA
enhanced	O
the	O
activity	O
of	O
a	O
heterologous	O
thymidine	O
kinase	O
promoter	O
in	O
monocytic	B-cell_type
cells	I-cell_type
but	O
not	O
other	O
cell	O
types	O
tested	O
.	O

These	O
results	O
indicate	O
that	O
the	O
monocyte/B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
PU.1	B-protein
and	O
the	O
Mono	B-protein
A	I-protein
and	I-protein
Mono	I-protein
B	I-protein
protein	I-protein
complexes	I-protein
act	O
in	O
concert	O
to	O
regulate	O
monocyte-specific	O
transcription	O
of	O
the	O
CSF-1	B-protein
receptor	I-protein
.	O

MoLECULAR	NULL
AND	NULL
CELLULAR	NULL
BroLOoGY	NULL
,	NULL
Dec.	NULL
1994	NULL
,	NULL
p.	NULL
8085-8095	NULL
0270-7306/94/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
Â©	NULL
1994	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

14	NULL
,	NULL
No	NULL
.	NULL

12	NULL
Identification	NULL
of	NULL
a	NULL
Region	NULL
Which	NULL
Directs	NULL
the	NULL
Monocytic	NULL
Activity	NULL
of	NULL
the	NULL
Colony-Stimulating	NULL
Factor	NULL
1	NULL
(	NULL
Macrophage	NULL
Colony-Stimulating	NULL
Factor	NULL
)	NULL
Receptor	NULL
Promoter	NULL
and	NULL
Binds	NULL
PEBP2/CBF	NULL
(	NULL
AML1	NULL
)	NULL
DONG-ER	NULL
ZHANG	NULL
,	NULL
``	NULL
'*	NULL
KEN-ICHIRO	NULL
FUJIOKA	NULL
,	NULL
*	NULL
CHRISTOPHER	NULL
J.	NULL
HETHERINGTON	NULL
,	NULL
!	NULL

LINDA	NULL
H.	NULL
SHAPIRO	NULL
,	NULL
HUI-MIN	NULL
CHEN	NULL
,	NULL
``	NULL
A.	NULL
THOMAS	NULL
LOOK	NULL
,	NULL
``	NULL
anp	NULL
DANIEL	NULL
G.	NULL
TENEN	NULL
Division	NULL
of	NULL
Hematology/Oncology	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Beth	NULL
Israel	NULL
Hospital	NULL
and	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
Massachusetts	NULL
02215	NULL
,	NULL
``	NULL
and	NULL
Department	NULL
of	NULL
Experimental	NULL
Oncology	NULL
,	NULL
St.	NULL
Jude	NULL
Children	NULL
's	NULL
Research	NULL
Hospital	NULL
,	NULL
Memphis	NULL
,	NULL
Tennessee	NULL
38101	NULL
Received	NULL
15	NULL
June	NULL
1994/Returned	NULL
for	NULL
modification	NULL
20	NULL
July	NULL
1994/Accepted	NULL
30	NULL
August	NULL
1994	NULL
The	NULL
receptor	NULL
for	NULL
the	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
or	NULL
colony-stimulating	NULL
factor	NULL
1	NULL
[	NULL
CSF-1	NULL
]	NULL
)	NULL
is	NULL
expressed	NULL
from	NULL
different	NULL
promoters	NULL
in	NULL
monocytic	NULL
cells	NULL
and	NULL
placental	NULL
trophoblasts	NULL
.	NULL

We	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
monocyte-specific	NULL
expression	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
is	NULL
regulated	NULL
at	NULL
the	NULL
level	NULL
of	NULL
transcription	NULL
by	NULL
a	NULL
tissue-specific	NULL
promoter	NULL
whose	NULL
activity	NULL
is	NULL
stimulated	NULL
by	NULL
the	NULL
monocyte/B-cell-specific	NULL
transcription	NULL
factor	NULL
PU.1	NULL
(	NULL
D.-E.	NULL
Zhang	NULL
,	NULL
C.	NULL
J.	NULL
Hetherington	NULL
,	NULL
H.-M.	NULL
Chen	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
,	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:373-381	NULL
,	NULL
1994	NULL
)	NULL
.	NULL

Here	NULL
we	NULL
report	NULL
that	NULL
the	NULL
tissue	NULL
specificity	NULL
of	NULL
this	NULL
promoter	NULL
is	NULL
also	NULL
mediated	NULL
by	NULL
sequences	NULL
in	NULL
a	NULL
region	NULL
II	NULL
(	NULL
bp	NULL
-88	NULL
to	NULL
-59	NULL
)	NULL
,	NULL
which	NULL
lies	NULL
10	NULL
bp	NULL
upstream	NULL
from	NULL
the	NULL
PU.1-binding	NULL
site	NULL
.	NULL

When	NULL
analyzed	NULL
by	NULL
DNase	NULL
footprinting	NULL
,	NULL
region	NULL
II	NULL
was	NULL
protected	NULL
preferentially	NULL
in	NULL
monocytic	NULL
cells	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
confirmed	NULL
that	NULL
region	NULL
II	NULL
interacts	NULL
specifically	NULL
with	NULL
nuclear	NULL
proteins	NULL
from	NULL
monocytic	NULL
cells	NULL
.	NULL

Two	NULL
gel	NULL
shift	NULL
complexes	NULL
(	NULL
Mono	NULL
A	NULL
and	NULL
Mono	NULL
B	NULL
)	NULL
were	NULL
formed	NULL
with	NULL
separate	NULL
sequence	NULL
elements	NULL
within	NULL
this	NULL
region	NULL
.	NULL

Competition	NULL
and	NULL
supershift	NULL
experiments	NULL
indicate	NULL
that	NULL
Mono	NULL
B	NULL
contains	NULL
a	NULL
member	NULL
of	NULL
the	NULL
polyomavirus	NULL
enhancer-binding	NULL
protein	NULL
2/core-binding	NULL
factor	NULL
(	NULL
PEBP2/CBF	NULL
)	NULL
family	NULL
,	NULL
which	NULL
includes	NULL
the	NULL
AML	NULL
]	NULL
gene	NULL
product	NULL
,	NULL
while	NULL
Mono	NULL
A	NULL
is	NULL
a	NULL
distinct	NULL
complex	NULL
preferentially	NULL
expressed	NULL
in	NULL
monocytic	NULL
cells	NULL
.	NULL

Promoter	NULL
constructs	NULL
with	NULL
mutations	NULL
in	NULL
these	NULL
sequence	NULL
elements	NULL
were	NULL
no	NULL
longer	NULL
expressed	NULL
specifically	NULL
in	NULL
monocytes	NULL
.	NULL

Furthermore	NULL
,	NULL
multimerized	NULL
region	NULL
II	NULL
sequence	NULL
elements	NULL
enhanced	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
heterologous	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
in	NULL
monocytic	NULL
cells	NULL
but	NULL
not	NULL
other	NULL
cell	NULL
types	NULL
tested	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
monocyte/B-cell-specific	NULL
transcription	NULL
factor	NULL
PU.1	NULL
and	NULL
the	NULL
Mono	NULL
A	NULL
and	NULL
Mono	NULL
B	NULL
protein	NULL
complexes	NULL
act	NULL
in	NULL
concert	NULL
to	NULL
regulate	NULL
monocyte-specific	NULL
transcription	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
.	NULL

During	NULL
hematopoiesis	NULL
,	NULL
pluripotent	NULL
stem	NULL
cells	NULL
in	NULL
the	NULL
bone	NULL
marrow	NULL
give	NULL
rise	NULL
to	NULL
committed	NULL
progenitor	NULL
cells	NULL
that	NULL
eventually	NULL
form	NULL
lineage-specific	NULL
mature	NULL
circulating	NULL
blood	NULL
cells	NULL
,	NULL
including	NULL
erythrocytes	NULL
,	NULL
T	NULL
and	NULL
B	NULL
lymphocytes	NULL
,	NULL
megakaryocytes	NULL
,	NULL
granulo-cytes	NULL
,	NULL
and	NULL
monocytes/macrophages	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
transcription	NULL
factors	NULL
regulating	NULL
the	NULL
lineage	NULL
commitment	NULL
of	NULL
hematopoietic	NULL
progenitor	NULL
cells	NULL
is	NULL
an	NULL
important	NULL
step	NULL
toward	NULL
understanding	NULL
the	NULL
mechanisms	NULL
of	NULL
cellular	NULL
differentiation	NULL
and	NULL
organ	NULL
development	NULL
.	NULL

For	NULL
example	NULL
,	NULL
the	NULL
transcription	NULL
factor	NULL
GATA-1	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
play	NULL
important	NULL
regulatory	NULL
roles	NULL
in	NULL
progenitor	NULL
cells	NULL
differentiating	NULL
in	NULL
the	NULL
erythrocyte	NULL
lineage	NULL
(	NULL
17	NULL
)	NULL
,	NULL
but	NULL
less	NULL
is	NULL
known	NULL
about	NULL
the	NULL
molecular	NULL
basis	NULL
of	NULL
monocytic	NULL
lineage	NULL
commitment	NULL
.	NULL

Many	NULL
experiments	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
colony-stimulating	NULL
factor	NULL
1	NULL
[	NULL
CSF-1	NULL
]	NULL
)	NULL
is	NULL
required	NULL
for	NULL
the	NULL
differentiation	NULL
,	NULL
proliferation	NULL
,	NULL
and	NULL
survival	NULL
of	NULL
monocytic	NULL
phagocytes	NULL
(	NULL
20	NULL
,	NULL
22	NULL
)	NULL
.	NULL

The	NULL
CSF-1	NULL
receptor	NULL
,	NULL
which	NULL
is	NULL
identical	NULL
to	NULL
the	NULL
product	NULL
of	NULL
the	NULL
c-fms	NULL
proto-oncogene	NULL
,	NULL
is	NULL
a	NULL
150-kDa	NULL
transmembrane	NULL
glycoprotein	NULL
with	NULL
an	NULL
intracellular	NULL
tyrosine	NULL
kinase	NULL
domain	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
is	NULL
normally	NULL
restricted	NULL
to	NULL
two	NULL
tissues	NULL
,	NULL
monocytes	NULL
and	NULL
placental	NULL
trophoblasts	NULL
,	NULL
in	NULL
which	NULL
it	NULL
is	NULL
regulated	NULL
by	NULL
different	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Division	NULL
of	NULL
Hematology/	NULL
Oncology	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Beth	NULL
Israel	NULL
Hospital	NULL
and	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
RE219	NULL
,	NULL
330	NULL
Brookline	NULL
Ave.	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02215	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
617	NULL
)	NULL
278-8930	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
617	NULL
)	NULL
735-3299	NULL
.	NULL

Electronic	NULL
mail	NULL
address	NULL
(	NULL
Internet	NULL
)	NULL
:	NULL
dzhang	NULL
@	NULL
bih.harvard.edu	NULL
.	NULL

8085	NULL
promoters	NULL
(	NULL
18	NULL
,	NULL
24	NULL
)	NULL
.	NULL

In	NULL
monocytes	NULL
,	NULL
transcription	NULL
starts	NULL
at	NULL
multiple	NULL
sites	NULL
within	NULL
200	NULL
bp	NULL
of	NULL
the	NULL
ATG	NULL
start	NULL
codon	NULL
.	NULL

In	NULL
placental	NULL
trophoblastic	NULL
cells	NULL
,	NULL
transcription	NULL
starts	NULL
26	NULL
kb	NULL
upstream	NULL
and	NULL
includes	NULL
an	NULL
additional	NULL
noncoding	NULL
exon	NULL
.	NULL

CSF-1	NULL
receptor	NULL
mRNA	NULL
and	NULL
surface	NULL
expression	NULL
of	NULL
the	NULL
protein	NULL
can	NULL
be	NULL
detected	NULL
in	NULL
the	NULL
early	NULL
stages	NULL
of	NULL
monocytic	NULL
differentiation	NULL
and	NULL
increases	NULL
dramatically	NULL
with	NULL
increasing	NULL
cell	NULL
maturity	NULL
within	NULL
this	NULL
lineage	NULL
(	NULL
19	NULL
,	NULL
25	NULL
)	NULL
.	NULL

Because	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
is	NULL
developmentally	NULL
regulated	NULL
and	NULL
restricted	NULL
to	NULL
the	NULL
monocytic	NULL
cells	NULL
,	NULL
it	NULL
can	NULL
be	NULL
used	NULL
as	NULL
a	NULL
model	NULL
with	NULL
which	NULL
to	NULL
study	NULL
the	NULL
mechanisms	NULL
regulating	NULL
commitment	NULL
to	NULL
the	NULL
monocytic	NULL
lineage	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
demonstrated	NULL
by	NULL
nuclear	NULL
run-on	NULL
analysis	NULL
that	NULL
tissue-specific	NULL
expression	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
is	NULL
regulated	NULL
at	NULL
a	NULL
transcriptional	NULL
level	NULL
in	NULL
monocytic	NULL
cells	NULL
(	NULL
30	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
sequences	NULL
500	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
transcriptional	NULL
origins	NULL
in	NULL
monocytic	NULL
cells	NULL
contain	NULL
tissue-specific	NULL
promoter	NULL
activity	NULL
(	NULL
18	NULL
,	NULL
30	NULL
)	NULL
.	NULL

The	NULL
B-cell-	NULL
and	NULL
myeloid	NULL
cell-specific	NULL
transcription	NULL
factor	NULL
PU.1	NULL
(	NULL
Spil	NULL
)	NULL
binds	NULL
to	NULL
sequences	NULL
within	NULL
this	NULL
promoter	NULL
region	NULL
and	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
this	NULL
tissue-specific	NULL
promoter	NULL
activity	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Although	NULL
important	NULL
for	NULL
expression	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
gene	NULL
by	NULL
monocytes	NULL
,	NULL
PU.1	NULL
is	NULL
also	NULL
found	NULL
in	NULL
B	NULL
lymphocytes	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
PU.1-binding	NULL
site	NULL
decreases	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
activity	NULL
in	NULL
a	NULL
tissue-specific	NULL
fashion	NULL
,	NULL
although	NULL
the	NULL
mutated	NULL
promoter	NULL
still	NULL
retains	NULL
residual	NULL
tissue-specific	NULL
activity	NULL
(	NULL
30	NULL
)	NULL
.	NULL

This	NULL
finding	NULL
suggests	NULL
that	NULL
there	NULL
are	NULL
probably	NULL
other	NULL
monocyte-specific	NULL
elements	NULL
that	NULL
direct	NULL
tissue	NULL
specific	NULL
expression	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
gene	NULL
in	NULL
combination	NULL
with	NULL
PU.1	NULL
.	NULL

In	NULL
8086	NULL
ZHANG	NULL
ET	NULL
AL	NULL
.	NULL

the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
investigated	NULL
this	NULL
possibility	NULL
by	NULL
promoter	NULL
deletion	NULL
analysis	NULL
and	NULL
DNA	NULL
binding	NULL
experiments	NULL
.	NULL

We	NULL
report	NULL
the	NULL
discovery	NULL
of	NULL
two	NULL
other	NULL
transcription	NULL
complexes	NULL
that	NULL
bind	NULL
just	NULL
upstream	NULL
of	NULL
the	NULL
PU.1	NULL
site	NULL
and	NULL
demonstrate	NULL
the	NULL
importance	NULL
of	NULL
their	NULL
binding	NULL
sites	NULL
for	NULL
CSF-1	NULL
receptor	NULL
monocyte-specific	NULL
promoter	NULL
activity	NULL
.	NULL

One	NULL
of	NULL
the	NULL
complexes	NULL
is	NULL
related	NULL
to	NULL
the	NULL
PEBP2/	NULL
CBF	NULL
family	NULL
member	NULL
AML1I	NULL
(	NULL
9	NULL
)	NULL
,	NULL
which	NULL
is	NULL
located	NULL
at	NULL
the	NULL
breakpoint	NULL
of	NULL
a	NULL
common	NULL
chromosome	NULL
translocation	NULL
in	NULL
acute	NULL
myelogenous	NULL
leukemia	NULL
(	NULL
AML	NULL
)	NULL
and	NULL
has	NULL
recently	NULL
been	NULL
reported	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
myeloid	NULL
cell-specific	NULL
expression	NULL
of	NULL
the	NULL
myeloperoxidase	NULL
gene	NULL
(	NULL
11	NULL
)	NULL
.	NULL

The	NULL
other	NULL
complex	NULL
is	NULL
expressed	NULL
preferentially	NULL
but	NULL
not	NULL
exclusively	NULL
in	NULL
monocytic	NULL
cells	NULL
.	NULL

These	NULL
two	NULL
complexes	NULL
bind	NULL
to	NULL
a	NULL
region	NULL
which	NULL
comprises	NULL
a	NULL
monocyte-specific	NULL
enhancer	NULL
element	NULL
which	NULL
,	NULL
along	NULL
with	NULL
the	NULL
adjacent	NULL
PU.1-binding	NULL
site	NULL
,	NULL
direct	NULL
monocyte-specific	NULL
expression	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
gene	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
culture	NULL
.	NULL

Human	NULL
monoblastic	NULL
U937	NULL
(	NULL
ATCC	NULL
CRL	NULL
1593	NULL
;	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
,	NULL
Rockville	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

,	NULL
B-lym-phoblastic	NULL
BJA-B	NULL
,	NULL
and	NULL
T-lymphoblastic	NULL
Jurkat	NULL
(	NULL
ATCC	NULL
TIB	NULL
152	NULL
)	NULL
and	NULL
REX	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
and	NULL
2	NULL
mM	NULL
L-glutamine	NULL
.	NULL

Human	NULL
promonocytic	NULL
THP-1	NULL
cells	NULL
(	NULL
ATCC	NULL
TIB	NULL
202	NULL
)	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
and	NULL
2	NULL
x	NULL
10~Â°	NULL
M	NULL
2-mercaptoctha-nol	NULL
.	NULL

The	NULL
human	NULL
Mono	NULL
Mac	NULL
6	NULL
cells	NULL
were	NULL
propagated	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Human	NULL
cervical	NULL
carcinoma	NULL
HeLa	NULL
cells	NULL
(	NULL
ATCC	NULL
CCL	NULL
2	NULL
)	NULL
were	NULL
maintained	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
newborn	NULL
calf	NULL
serum	NULL
and	NULL
2	NULL
mM	NULL
L-glutamine	NULL
.	NULL

Transient	NULL
transfections	NULL
.	NULL

For	NULL
analysis	NULL
of	NULL
deletion	NULL
constructs	NULL
,	NULL
U937	NULL
and	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
electroporation	NULL
in	NULL
serum-free	NULL
Iscove	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
at	NULL
960	NULL
mF	NULL
and	NULL
170	NULL
V.	NULL
The	NULL
detailed	NULL
transfection	NULL
procedures	NULL
were	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
14	NULL
)	NULL
except	NULL
that	NULL
the	NULL
final	NULL
cell	NULL
concentration	NULL
was	NULL
10Â°	NULL
cells/ml	NULL
,	NULL
and	NULL
0.2	NULL
ml	NULL
of	NULL
cells	NULL
was	NULL
aliquoted	NULL
into	NULL
each	NULL
cuvette	NULL
.	NULL

These	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
Iscove	NULL
's	NULL
medium	NULL
containing	NULL
15	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
before	NULL
harvest	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
8	NULL
h	NULL
post-transfection	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
lysis	NULL
buffer	NULL
,	NULL
and	NULL
luciferase	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
1	NULL
,	NULL
14	NULL
)	NULL
.	NULL

The	NULL
transfection	NULL
efficiency	NULL
was	NULL
normalized	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
the	NULL
level	NULL
of	NULL
the	NULL
secreted	NULL
form	NULL
of	NULL
the	NULL
human	NULL
placental	NULL
alkaline	NULL
phosphatase	NULL
(	NULL
SEAP	NULL
)	NULL
activity	NULL
(	NULL
13	NULL
)	NULL
,	NULL
and	NULL
the	NULL
data	NULL
were	NULL
calculated	NULL
in	NULL
relative	NULL
light	NULL
units	NULL
per	NULL
unit	NULL
of	NULL
SEAP	NULL
activity	NULL
.	NULL

For	NULL
analysis	NULL
of	NULL
other	NULL
constructs	NULL
,	NULL
transfection	NULL
experiments	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Deletion	NULL
constructs	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
proximal	NULL
promoter	NULL
.	NULL

Plasmid	NULL
a	NULL
pB5/-480	NULL
was	NULL
fashioned	NULL
by	NULL
cloning	NULL
the	NULL
proximal	NULL
(	NULL
monocytic	NULL
)	NULL
human	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
550-bp	NULL
Sacl	NULL
fragment	NULL
into	NULL
the	NULL
promoterless	NULL
and	NULL
enhancerless	NULL
luciferase	NULL
vector	NULL
pGL2-basic	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

Assigning	NULL
the	NULL
most	NULL
5	NULL
major	NULL
transcription	NULL
start	NULL
site	NULL
in	NULL
monocytic	NULL
cells	NULL
as	NULL
+1	NULL
(	NULL
18	NULL
)	NULL
,	NULL
this	NULL
Sacl	NULL
fragment	NULL
contains	NULL
CSF-1	NULL
receptor	NULL
sequences	NULL
from	NULL
-480	NULL
to	NULL
+70	NULL
bp	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Plasmids	NULL
pB5/-294	NULL
,	NULL
pBS5/-214	NULL
,	NULL
pB5/-85	NULL
,	NULL
and	NULL
pB5/-25	NULL
were	NULL
constructed	NULL
by	NULL
using	NULL
PCR	NULL
with	NULL
the	NULL
pB5/-480	NULL
template	NULL
.	NULL

The	NULL
primers	NULL
used	NULL
for	NULL
PCR	NULL
were	NULL
5-GATCTIGCC	NULL
CGGGCCACCTGATCA-3	NULL
'	NULL
(	NULL
-294	NULL
)	NULL
,	NULL
5-TCTCITTCTCCCGG	NULL
GACCCCTITTGA-3	NULL
'	NULL
(	NULL
-214	NULL
)	NULL
,	NULL
5-CTTAAAGACCCGGGATTT	NULL
CCAAA-3	NULL
'	NULL
(	NULL
-85	NULL
)	NULL
,	NULL
and	NULL
5-AGGATCAGCCCGGGGAGGAG	NULL
GAA-3	NULL
'	NULL
(	NULL
-25	NULL
)	NULL
for	NULL
the	NULL
5	NULL
ends	NULL
and	NULL
CGTCTTCCA-3	NULL
'	NULL
for	NULL
the	NULL
3	NULL
'	NULL
end	NULL
.	NULL

These	NULL
promoter	NULL
fragments	NULL
were	NULL
placed	NULL
in	NULL
plasmid	NULL
pGL2-basic	NULL
digested	NULL
with	NULL
restriction	NULL
endonucleases	NULL
Sacl	NULL
and	NULL
XmanI	NULL
.	NULL

The	NULL
additional	NULL
plasmids	NULL
pBS/	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

-407	NULL
and	NULL
pBS5/-185	NULL
were	NULL
constructed	NULL
by	NULL
truncation	NULL
of	NULL
the	NULL
5'-proximal	NULL
promoter	NULL
fragment	NULL
of	NULL
pB5/-480	NULL
,	NULL
using	NULL
NsiI-KpnI	NULL
or	NULL
Apal-KpniI	NULL
double	NULL
restriction	NULL
digests	NULL
.	NULL

Nuclear	NULL
extracts	NULL
.	NULL

Cells	NULL
were	NULL
grown	NULL
to	NULL
the	NULL
log	NULL
phase	NULL
and	NULL
harvested	NULL
for	NULL
nuclear	NULL
protein	NULL
extraction	NULL
.	NULL

Nuclear	NULL
extracts	NULL
for	NULL
DNase	NULL
I	NULL
footprinting	NULL
were	NULL
prepared	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
for	NULL
band	NULL
shift	NULL
were	NULL
prepared	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Dignam	NULL
et	NULL
al	NULL
.	NULL

(	NULL
3	NULL
)	NULL
with	NULL
all	NULL
of	NULL
the	NULL
proteinase	NULL
inhibitors	NULL
as	NULL
described	NULL
for	NULL
DNase	NULL
I	NULL
footprinting	NULL
(	NULL
31	NULL
)	NULL
.	NULL

DNase	NULL
I	NULL
footprinting	NULL
.	NULL

A	NULL
540-bp	NULL
fragment	NULL
extending	NULL
from	NULL
bp	NULL
-416	NULL
to	NULL
+124	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
was	NULL
digested	NULL
with	NULL
BamHI	NULL
and	NULL
Xhol	NULL
to	NULL
release	NULL
the	NULL
promoter	NULL
fragment	NULL
from	NULL
the	NULL
vector	NULL
pXP2	NULL
(	NULL
30	NULL
)	NULL
.	NULL

*Â°P	NULL
labeling	NULL
at	NULL
Xhol	NULL
site	NULL
of	NULL
the	NULL
DNA	NULL
fragment	NULL
and	NULL
performance	NULL
of	NULL
the	NULL
DNase	NULL
I	NULL
footprinting	NULL
were	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
31	NULL
)	NULL
.	NULL

EMSA	NULL
.	NULL

P-labeled	NULL
double-stranded	NULL
oligonucleotides	NULL
for	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
were	NULL
prepared	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
30	NULL
)	NULL
.	NULL

All	NULL
double-stranded	NULL
oligonucleotides	NULL
have	NULL
Sa/l	NULL
and	NULL
Xhol	NULL
sticky	NULL
ends	NULL
at	NULL
the	NULL
upstream	NULL
and	NULL
downstream	NULL
ends	NULL
,	NULL
respectively	NULL
.	NULL

DNA	NULL
binding	NULL
and	NULL
electro-phoresis	NULL
conditions	NULL
were	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
30	NULL
)	NULL
.	NULL

CSF-1	NULL
receptor	NULL
fromoter	NULL
oligonucleotide	NULL
(	NULL
0.25	NULL
ng	NULL
)	NULL
was	NULL
end	NULL
labeled	NULL
with	NULL
[	NULL
y-	NULL
>	NULL
Â°P	NULL
]	NULL
ATP	NULL
and	NULL
incubated	NULL
with	NULL
1	NULL
ug	NULL
of	NULL
double-stranded	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
and	NULL
50	NULL
ng	NULL
of	NULL
unlabeled	NULL
coding	NULL
(	NULL
single	NULL
)	NULL
-stranded	NULL
bp	NULL
-88	NULL
to	NULL
-59	NULL
oligonucleotide	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
nuclear	NULL
protein	NULL
.	NULL

(	NULL
The	NULL
reactions	NULL
presented	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
do	NULL
not	NULL
contain	NULL
unlabeled	NULL
single-stranded	NULL
oligonucleotide	NULL
.	NULL
)	NULL

For	NULL
competition	NULL
experiments	NULL
,	NULL
an	NULL
excess	NULL
of	NULL
double-stranded	NULL
unlabeled	NULL
oligonucleotides	NULL
(	NULL
exact	NULL
amounts	NULL
are	NULL
specified	NULL
in	NULL
the	NULL
figure	NULL
legends	NULL
)	NULL
were	NULL
added	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
mixture	NULL
together	NULL
with	NULL
the	NULL
other	NULL
components	NULL
.	NULL

For	NULL
supershift	NULL
experiments	NULL
,	NULL
1	NULL
pl	NULL
of	NULL
an	NULL
antiserum	NULL
raised	NULL
against	NULL
a	NULL
17-amino-acid	NULL
N-terminal	NULL
peptide	NULL
from	NULL
AML1	NULL
(	NULL
7	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
mixture	NULL
10	NULL
min	NULL
prior	NULL
to	NULL
addition	NULL
of	NULL
the	NULL
probe	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
1	NULL
jl	NULL
of	NULL
an	NULL
antiserum	NULL
raised	NULL
against	NULL
transcription	NULL
factor	NULL
Oct-1	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotech-nology	NULL
,	NULL
Inc.	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
Calif.	NULL
)	NULL
was	NULL
used	NULL
instead	NULL
.	NULL

Site-directed	NULL
mutagenesis	NULL
of	NULL
region	NULL
II	NULL
.	NULL

The	NULL
wild-type	NULL
CSF-1	NULL
receptor	NULL
promoter-luciferase	NULL
constructs	NULL
p540M-CSF-R-luc	NULL
and	NULL
pM-CSF-R-luc	NULL
were	NULL
described	NULL
previously	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Mutated	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
fragments	NULL
were	NULL
generated	NULL
by	NULL
PCR	NULL
,	NULL
with	NULL
plasmid	NULL
pS40M-CSF-R-luc	NULL
as	NULL
a	NULL
template	NULL
.	NULL

Primer	NULL
A	NULL
AGG-3	NULL
'	NULL
)	NULL
was	NULL
used	NULL
with	NULL
either	NULL
primer	NULL
C	NULL
(	NULL
5'-GGGGTACCTG	NULL
GGTCTTTAAGAAG-3	NULL
'	NULL
)	NULL
or	NULL
primer	NULL
E	NULL
(	NULL
5-TCGAGCAGGTA	NULL
CCTTACAGAGTTTGGAAATCTITTG-3	NULL
'	NULL
)	NULL
to	NULL
generate	NULL
PCR	NULL
fragment	NULL
1	NULL
or	NULL
3	NULL
,	NULL
respectively	NULL
.	NULL

Primer	NULL
B	NULL
(	NULL
5-GGGGTACCCCT	NULL
CGGTGGGGAAGTGGCA-3	NULL
'	NULL
)	NULL
was	NULL
used	NULL
with	NULL
either	NULL
primer	NULL
D	NULL
(	NULL
5-TCGACAGGTACCATAAACTCTGTGGTTGCCITT	NULL
GC-3	NULL
'	NULL
)	NULL
,	NULL
primer	NULL
F	NULL
(	NULL
5-GGGGTACCTGCCTAGCTAAAAG	NULL
G-3	NULL
'	NULL
)	NULL
,	NULL
or	NULL
primer	NULL
G	NULL
(	NULL
5'-GGGGTACCGATCAGCCCAAG-3	NULL
'	NULL
)	NULL
to	NULL
generate	NULL
PCR	NULL
fragment	NULL
2	NULL
,	NULL
4	NULL
,	NULL
or	NULL
5	NULL
,	NULL
respectively	NULL
.	NULL

PCR	NULL
fragments	NULL
1	NULL
and	NULL
3	NULL
were	NULL
digested	NULL
with	NULL
BamHI	NULL
and	NULL
KpnI	NULL
.	NULL

PCR	NULL
fragments	NULL
2	NULL
,	NULL
4	NULL
,	NULL
and	NULL
5	NULL
were	NULL
digested	NULL
with	NULL
KpnI	NULL
and	NULL
Sacl	NULL
.	NULL

Digested	NULL
PCR	NULL
fragments	NULL
1	NULL
and	NULL
2	NULL
or	NULL
3	NULL
and	NULL
4	NULL
were	NULL
ligated	NULL
with	NULL
BamHI-	NULL
and	NULL
Sacl-digested	NULL
vector	NULL
pXP2	NULL
to	NULL
construct	NULL
pM-CSF-R	NULL
(	NULL
MA	NULL
)	NULL
-luec	NULL
or	NULL
pM-CSF-R	NULL
(	NULL
MB	NULL
)	NULL
-luc	NULL
,	NULL
respectively	NULL
.	NULL

Digested	NULL
PCR	NULL
fragments	NULL
1	NULL
and	NULL
5	NULL
were	NULL
ligated	NULL
with	NULL
BamHI-	NULL
and	NULL
Sacl-digested	NULL
vector	NULL
pXP2	NULL
to	NULL
construct	NULL
pM-CSF-R	NULL
(	NULL
DD	NULL
)	NULL
-luc	NULL
.	NULL

The	NULL
sequences	NULL
of	NULL
the	NULL
mutant	NULL
constructs	NULL
were	NULL
confirmed	NULL
by	NULL
the	NULL
dideoxy-chain	NULL
termination	NULL
method	NULL
.	NULL

The	NULL
mutated	NULL
constructs	NULL
pM-CSF-R	NULL
(	NULL
MA	NULL
)	NULL
-lue	NULL
and	NULL
pM-CSF-R	NULL
(	NULL
MB	NULL
)	NULL
-lue	NULL
changed	NULL
the	NULL
sequence	NULL
at	NULL
bp	NULL
-86	NULL
to	NULL
-79	NULL
from	NULL
AGATTTCC	NULL
to	NULL
GGTAC-CAT	NULL
and	NULL
the	NULL
sequence	NULL
at	NULL
bp	NULL
-71	NULL
to	NULL
-62	NULL
from	NULL
GTGGTT-GCCT	NULL
to	NULL
CTAAGGTACC	NULL
.	NULL

The	NULL
construct	NULL
pM-CSF-R	NULL
(	NULL
DD	NULL
)	NULL
-luc	NULL
deleted	NULL
bp	NULL
-86	NULL
to	NULL
-37	NULL
from	NULL
the	NULL
wild-type	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
.	NULL

VoL	NULL
.	NULL

14	NULL
,	NULL
1994	NULL
CSF-1	NULL
RECEPTOR	NULL
MONOCYTIC	NULL
REGULATORY	NULL
ELEMENT	NULL
8087	NULL
A	NULL
T	NULL
U	NULL
T	NULL
T	NULL
I	NULL
T	NULL
I	NULL
T	NULL
mo-	NULL
-	NULL
-4	NULL
$	NULL
0	NULL
ug37	NULL
1269	NULL
31	NULL
168	NULL
a	NULL
BR	NULL
Jurkat	NULL
Md	NULL
2	NULL
07	NULL
8	NULL
51	NULL
â	NULL
-	NULL
4	NULL
07	NULL
mttummmmnmmememmmemmur	NULL
6	NULL
4	NULL
11	NULL
10	NULL
2	NULL
7	NULL
4	NULL
3	NULL
68	NULL
â	NULL
_	NULL
29	NULL
4	NULL
+	NULL
317	NULL
8	NULL
noma	NULL
4	NULL
0	NULL
4g	NULL
100	NULL
_	NULL
m	NULL
2	NULL
1	NULL
4	NULL
ones	NULL
v	NULL
1498	NULL
37	NULL
ssd	NULL
3	NULL
3	NULL
30	NULL
8	NULL
2	NULL
â	NULL
3	NULL
1	NULL
8	NULL
5	NULL
v	NULL
913	NULL
23	NULL
mma	NULL
3	NULL
312	NULL
8	NULL
2	NULL
-	NULL
_8	NULL
5	NULL
Momsen	NULL
,	NULL
259	NULL
6	NULL
amine	NULL
moo	NULL
-25	NULL
458	NULL
11	NULL
174	NULL
4	NULL
pGL2-Basic	NULL
|P	NULL
118	NULL
3	NULL
a	NULL
;	NULL
1	NULL
L	NULL
1	NULL
1	NULL
L	NULL
1	NULL
1	NULL
mui	NULL
tui	NULL
RLU	NULL
%	NULL
Activity	NULL
RLU	NULL
%	NULL
Activity	NULL
0	NULL
1000	NULL
2000	NULL
3000	NULL
4000	NULL
u937	NULL
Jurkat	NULL
Promoter	NULL
Deletion	NULL
Reporter	NULL
Gene	NULL
Activity	NULL
(	NULL
in	NULL
RLU	NULL
)	NULL
Mean	NULL
Reporter	NULL
Gene	NULL
Activity	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Transient	NULL
transfection	NULL
analysis	NULL
of	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
activity	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Schematic	NULL
representations	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
5	NULL
'	NULL
upstream	NULL
sequence-luciferase	NULL
constructs	NULL
.	NULL

These	NULL
constructs	NULL
and	NULL
the	NULL
promoterless	NULL
pGL2-basic	NULL
vector	NULL
alone	NULL
were	NULL
transfected	NULL
into	NULL
U937	NULL
monocytic	NULL
leukemia	NULL
cells	NULL
and	NULL
Jurkat	NULL
T-lymphoid	NULL
leukemia	NULL
cells	NULL
in	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

The	NULL
reporter	NULL
gene	NULL
activity	NULL
of	NULL
each	NULL
construct	NULL
in	NULL
relative	NULL
light	NULL
units	NULL
(	NULL
RLU	NULL
)	NULL
is	NULL
shown	NULL
as	NULL
a	NULL
bar	NULL
chart	NULL
.	NULL

To	NULL
control	NULL
for	NULL
differences	NULL
in	NULL
transfection	NULL
efficiency	NULL
,	NULL
we	NULL
cotransfected	NULL
a	NULL
plasmid	NULL
containing	NULL
a	NULL
SEAP	NULL
gene	NULL
driven	NULL
by	NULL
the	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Mean	NULL
reporter	NULL
gene	NULL
activity	NULL
in	NULL
RLU	NULL
per	NULL
unit	NULL
of	NULL
SEAP	NULL
activity	NULL
tabulated	NULL
along	NULL
with	NULL
the	NULL
percent	NULL
activity	NULL
relative	NULL
to	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
-214	NULL
promoter	NULL
in	NULL
U937	NULL
cells	NULL
.	NULL

Heterologous	NULL
promoter	NULL
analysis	NULL
.	NULL

The	NULL
head-to-tail-ligated	NULL
tetramer	NULL
and	NULL
hexamer	NULL
of	NULL
the	NULL
region	NULL
II	NULL
wild-type	NULL
double-stranded	NULL
oligonucleotide	NULL
(	NULL
-88	NULL
to	NULL
-59	NULL
)	NULL
were	NULL
inserted	NULL
into	NULL
the	NULL
Sall	NULL
site	NULL
of	NULL
pBluescript	NULL
(	NULL
KS-	NULL
)	NULL
,	NULL
digested	NULL
with	NULL
Xhol	NULL
and	NULL
HindIII	NULL
,	NULL
blunt	NULL
ended	NULL
,	NULL
and	NULL
religated	NULL
into	NULL
Smal-digested	NULL
pT8l-luc	NULL
to	NULL
form	NULL
p	NULL
(	NULL
Mono	NULL
)	NULL
,	NULL
T81-luc	NULL
,	NULL
p	NULL
(	NULL
Mono	NULL
)	NULL
,	NULL
T8l-luc	NULL
,	NULL
and	NULL
p	NULL
(	NULL
Monod	NULL
)	NULL
se	NULL
T81-luc	NULL
.	NULL

p	NULL
(	NULL
Mono	NULL
)	NULL
,	NULL
T81-lue	NULL
and	NULL
p	NULL
(	NULL
Mono	NULL
)	NULL
,	NULL
T81-luc	NULL
contain	NULL
the	NULL
tetramer	NULL
and	NULL
hexamer	NULL
of	NULL
region	NULL
II	NULL
in	NULL
the	NULL
5	NULL
'	NULL
site	NULL
of	NULL
the	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
in	NULL
pT81-luc	NULL
in	NULL
the	NULL
same	NULL
orientation	NULL
as	NULL
in	NULL
the	NULL
parental	NULL
promoter	NULL
.	NULL

p	NULL
(	NULL
Mono	NULL
)	NULL
,	NULL
g	NULL
T81-luc	NULL
contains	NULL
the	NULL
hexamer	NULL
of	NULL
region	NULL
II	NULL
in	NULL
the	NULL
reversed	NULL
orientation	NULL
.	NULL

These	NULL
constructs	NULL
were	NULL
transfected	NULL
into	NULL
monocytic	NULL
and	NULL
nonmonocytic	NULL
cell	NULL
lines	NULL
to	NULL
compare	NULL
the	NULL
promoter	NULL
activity	NULL
relative	NULL
to	NULL
that	NULL
of	NULL
the	NULL
basal	NULL
herpes	NULL
simplex	NULL
virus	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
construct	NULL
pT81-lue	NULL
(	NULL
10	NULL
,	NULL
30	NULL
)	NULL
.	NULL

RESULTS	NULL
Deletion	NULL
analysis	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
demonstrates	NULL
that	NULL
as	NULL
little	NULL
as	NULL
85	NULL
bp	NULL
of	NULL
5	NULL
'	NULL
flanking	NULL
DNA	NULL
directs	NULL
monocytic	NULL
expression	NULL
.	NULL

Previous	NULL
studies	NULL
of	NULL
the	NULL
human	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
indicated	NULL
that	NULL
the	NULL
proximal	NULL
promoter	NULL
adjacent	NULL
to	NULL
exon	NULL
2	NULL
displayed	NULL
specificity	NULL
for	NULL
cells	NULL
of	NULL
the	NULL
myeloid/	NULL
macrophage	NULL
lineage	NULL
(	NULL
18	NULL
,	NULL
30	NULL
)	NULL
.	NULL

To	NULL
further	NULL
examine	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
proximal	NULL
promoter	NULL
and	NULL
to	NULL
identify	NULL
the	NULL
cis-acting	NULL
regulatory	NULL
elements	NULL
responsible	NULL
for	NULL
tissue	NULL
specificity	NULL
,	NULL
we	NULL
generated	NULL
a	NULL
series	NULL
of	NULL
deletion	NULL
mutants	NULL
and	NULL
tested	NULL
them	NULL
by	NULL
a	NULL
transient	NULL
transfection	NULL
assay	NULL
in	NULL
U937	NULL
and	NULL
Jurkat	NULL
cells	NULL
,	NULL
using	NULL
luciferase	NULL
reporter	NULL
constructs	NULL
.	NULL

The	NULL
construct	NULL
containing	NULL
480	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
5	NULL
'	NULL
major	NULL
transcription	NULL
initiation	NULL
site	NULL
in	NULL
human	NULL
monocytic	NULL
cells	NULL
(	NULL
18	NULL
)	NULL
was	NULL
expressed	NULL
at	NULL
approximately	NULL
10-fold-higher	NULL
levels	NULL
in	NULL
U937	NULL
(	NULL
monocytic	NULL
)	NULL
cells	NULL
than	NULL
in	NULL
Jurkat	NULL
(	NULL
T-lymphocytic	NULL
)	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
the	NULL
promoter	NULL
in	NULL
both	NULL
cell	NULL
lines	NULL
increased	NULL
with	NULL
deletions	NULL
extending	NULL
to	NULL
-214	NULL
bp	NULL
,	NULL
suggesting	NULL
the	NULL
loss	NULL
of	NULL
sequences	NULL
mediating	NULL
transcriptional	NULL
repression	NULL
.	NULL

A	NULL
construct	NULL
retaining	NULL
only	NULL
85	NULL
bp	NULL
of	NULL
the	NULL
promoter	NULL
upstream	NULL
of	NULL
the	NULL
initiation	NULL
site	NULL
retained	NULL
most	NULL
of	NULL
the	NULL
promoter	NULL
activity	NULL
of	NULL
the	NULL
-214	NULL
bp	NULL
construct	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
tissue-restricted	NULL
pattern	NULL
of	NULL
expression	NULL
,	NULL
with	NULL
15-fold-higher	NULL
levels	NULL
of	NULL
activity	NULL
in	NULL
U937	NULL
cells	NULL
than	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
there	NULL
are	NULL
both	NULL
negative	NULL
and	NULL
positive	NULL
cis-acting	NULL
elements	NULL
in	NULL
the	NULL
480-bp	NULL
region	NULL
immediately	NULL
upstream	NULL
of	NULL
the	NULL
major	NULL
CSF-1	NULL
receptor	NULL
initiation	NULL
site	NULL
that	NULL
are	NULL
responsible	NULL
for	NULL
the	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
activity	NULL
and	NULL
indicate	NULL
the	NULL
presence	NULL
of	NULL
important	NULL
positive	NULL
elements	NULL
in	NULL
a	NULL
fragment	NULL
containing	NULL
only	NULL
85	NULL
bp	NULL
of	NULL
5Â°	NULL
flanking	NULL
DNA	NULL
relative	NULL
to	NULL
the	NULL
major	NULL
start	NULL
site	NULL
of	NULL
transcription	NULL
.	NULL

Nuclear	NULL
proteins	NULL
from	NULL
monocytic	NULL
cells	NULL
interact	NULL
with	NULL
the	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
in	NULL
a	NULL
cell-type-specific	NULL
manner	NULL
.	NULL

cis-acting	NULL
elements	NULL
direct	NULL
the	NULL
promoter	NULL
's	NULL
activity	NULL
through	NULL
interaction	NULL
with	NULL
ubiquitous	NULL
and	NULL
tissue	NULL
specific	NULL
trans-acting	NULL
factors	NULL
.	NULL

To	NULL
further	NULL
analyze	NULL
the	NULL
factors	NULL
mediating	NULL
monocyte-specific	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
activity	NULL
,	NULL
we	NULL
performed	NULL
DNase	NULL
I	NULL
footprinting	NULL
with	NULL
a	NULL
DNA	NULL
fragment	NULL
containing	NULL
the	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
and	NULL
nuclear	NULL
proteins	NULL
from	NULL
Mono	NULL
Mac	NULL
6	NULL
and	NULL
U937	NULL
monocytic	NULL
leukemia	NULL
cells	NULL
and	NULL
HeLa	NULL
cervical	NULL
carcinoma	NULL
epithelial	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
three	NULL
regions	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
(	NULL
bp	NULL
-150	NULL
to	NULL
+60	NULL
)	NULL
interacted	NULL
with	NULL
nuclear	NULL
proteins	NULL
from	NULL
monocytic	NULL
cells	NULL
.	NULL

When	NULL
coding-strand-labeled	NULL
DNA	NULL
fragments	NULL
were	NULL
used	NULL
as	NULL
probes	NULL
,	NULL
nuclear	NULL
proteins	NULL
from	NULL
both	NULL
monocytic	NULL
and	NULL
nonmonocytic	NULL
cells	NULL
protected	NULL
region	NULL
I	NULL
,	NULL
including	NULL
the	NULL
8088	NULL
ZHANG	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
G/A	NULL
-163	NULL
I	NULL
Gat	NULL
-106	NULL
-	NULL
HeLa	NULL
Mono	NULL
0	NULL
50	NULL
100	NULL
50	NULL
100	NULL
C	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BroL	NULL
.	NULL

B	NULL
U937	NULL
HeLa	NULL
Mono	NULL
Â©/	NULL
,	NULL
0	NULL
50	NULL
10050	NULL
100	NULL
50	NULL
100	NULL
+25	NULL
-	NULL
``	NULL
+1	NULL
-30	NULL
-54	NULL
-170	NULL
Region	NULL
III	NULL
T	NULL
-150	NULL
CCCTGCCCCA	NULL
GACTGCGACC	NULL
CCTCCCTCTT	NULL
CTGACGCTGG	NULL
GGAGGGAGAA	NULL
GGGACGGGGT	NULL
Region	NULL
II	NULL
1	NULL
GGGTTCAAGG	NULL
CTTTGTTTTC	NULL
TTCTTAAAGA	NULL
CCCAAGTTCC	NULL
GAAACAAAAG	NULL
AAGAATTTCT	NULL
Region	NULL
I	NULL
T	NULL
-90	NULL
CCCAAGATTT	NULL
GGGTTCTAAA	NULL
I	NULL
CCAAACTCTG	NULL
TGGTTGCCTT	NULL
GGTTTGAGAC	NULL
ACCAACGGAA	NULL
CGGATCGATT	NULL
TTCCCCTTCT	NULL
TCTCCTAGTC	NULL
|	NULL
I	NULL
I	NULL
ic	NULL
_n	NULL
.	NULL

romain	NULL
aad	NULL
GCCTAGCTAA	NULL
AAGGGGAAGA	NULL
AGAGGATCAG	NULL
-30	NULL
CCCAAGGAGG	NULL
AGGAAGAGGA	NULL
AAACAAGACA	NULL
AACAGCCAGT	NULL
GCAGAGGAGA	NULL
GGAACGTGTG	NULL
GGGTTCCTCC	NULL
folk	NULL
TCCTTCTCCT	NULL
TTEGTTCTGT	NULL
TTGTCGGTCA	NULL
CGTCTCCTCT	NULL
CCTTGCACAC	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

DNase	NULL
I	NULL
footprinting	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
.	NULL

The	NULL
CSF-1	NULL
receptor	NULL
5	NULL
'	NULL
upstream	NULL
DNA	NULL
fragment	NULL
was	NULL
end	NULL
labeled	NULL
on	NULL
the	NULL
coding	NULL
strand	NULL
(	NULL
A	NULL
)	NULL
or	NULL
noncoding	NULL
strand	NULL
(	NULL
B	NULL
)	NULL
and	NULL
incubated	NULL
with	NULL
0	NULL
,	NULL
50	NULL
,	NULL
and	NULL
100	NULL
pg	NULL
of	NULL
nuclear	NULL
protein	NULL
from	NULL
U937	NULL
,	NULL
HeLa	NULL
,	NULL
or	NULL
Mono	NULL
Mac	NULL
6	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
4	NULL
ug	NULL
of	NULL
double-stranded	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
.	NULL

Lane	NULL
G/A	NULL
is	NULL
a	NULL
marker	NULL
consisting	NULL
of	NULL
the	NULL
probe	NULL
DNA	NULL
subjected	NULL
to	NULL
G+	NULL
A-specific	NULL
Maxam-Gilbert	NULL
cleavage	NULL
.	NULL

Numbers	NULL
at	NULL
the	NULL
left	NULL
side	NULL
of	NULL
each	NULL
panel	NULL
indicate	NULL
the	NULL
nucleotides	NULL
upstream	NULL
(	NULL
-	NULL
)	NULL
or	NULL
downstream	NULL
(	NULL
+	NULL
)	NULL
of	NULL
the	NULL
major	NULL
transcription	NULL
initiation	NULL
site	NULL
(	NULL
+1	NULL
)	NULL
.	NULL

Sequences	NULL
protected	NULL
from	NULL
DNase	NULL
I	NULL
digestion	NULL
are	NULL
indicated	NULL
by	NULL
brackets	NULL
,	NULL
and	NULL
the	NULL
roman	NULL
numerals	NULL
refer	NULL
to	NULL
the	NULL
entire	NULL
protected	NULL
region	NULL
.	NULL

(	NULL
C	NULL
)	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
sequence	NULL
and	NULL
three	NULL
protected	NULL
regions	NULL
.	NULL

Protected	NULL
regions	NULL
from	NULL
the	NULL
labeled	NULL
coding	NULL
strand	NULL
and	NULL
noncoding	NULL
strand	NULL
are	NULL
indicated	NULL
by	NULL
brackets	NULL
above	NULL
and	NULL
below	NULL
the	NULL
DNA	NULL
sequence	NULL
,	NULL
respectively	NULL
.	NULL

disappearance	NULL
of	NULL
a	NULL
DNA	NULL
band	NULL
around	NULL
bp	NULL
-41	NULL
and	NULL
the	NULL
appearance	NULL
of	NULL
hypersensitive	NULL
bands	NULL
around	NULL
bp	NULL
-44	NULL
to	NULL
-48	NULL
.	NULL

When	NULL
noncoding-strand-labeled	NULL
DNA	NULL
fragments	NULL
were	NULL
used	NULL
as	NULL
probes	NULL
,	NULL
only	NULL
the	NULL
nuclear	NULL
proteins	NULL
from	NULL
U937	NULL
and	NULL
Mono	NULL
Mac	NULL
6	NULL
monocytic	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
HeLa	NULL
cells	NULL
,	NULL
showed	NULL
strong	NULL
protection	NULL
in	NULL
region	NULL
I	NULL
.	NULL

A	NULL
hypersensitive	NULL
site	NULL
at	NULL
bp	NULL
-47	NULL
of	NULL
region	NULL
I	NULL
developed	NULL
when	NULL
noncoding-strand-labeled	NULL
DNA	NULL
fragments	NULL
interacted	NULL
with	NULL
nuclear	NULL
proteins	NULL
from	NULL
monocytic	NULL
cells	NULL
.	NULL

Region	NULL
I	NULL
is	NULL
bound	NULL
by	NULL
the	NULL
monocytic	NULL
cell-	NULL
and	NULL
B-cell-specific	NULL
transcription	NULL
factor	NULL
PU.1	NULL
and	NULL
another	NULL
non-tissue-specific	NULL
factor	NULL
(	NULL
refer-	NULL
VoL	NULL
.	NULL

14	NULL
,	NULL
1994	NULL
C	NULL
Th	NULL
Mo	NULL
He	NULL
Ju	NULL
B	NULL
U	NULL
U	NULL
3	NULL
.	NULL

â	NULL
ï¬ï¬a	NULL
(	NULL
0	NULL
Mono	NULL
A-	NULL
>	NULL
Mono	NULL
B-2	NULL
<	NULL
-	NULL
Mono	NULL
A	NULL
<	NULL
-	NULL
Mono	NULL
B	NULL
F	NULL
9	NULL
10	NULL
Lane	NULL
:	NULL
1	NULL
6	NULL
7	NULL
8	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

EMSA	NULL
of	NULL
DNA-protein	NULL
interactions	NULL
at	NULL
region	NULL
II	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
with	NULL
nuclear	NULL
proteins	NULL
from	NULL
different	NULL
cell	NULL
lines	NULL
.	NULL

A	NULL
double-stranded	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
oligonucleotide	NULL
extending	NULL
from	NULL
bp	NULL
-88	NULL
to	NULL
-59	NULL
was	NULL
end	NULL
labeled	NULL
and	NULL
incubated	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
nuclear	NULL
protein	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10	NULL
ug	NULL
of	NULL
nuclear	NULL
protein	NULL
prepared	NULL
from	NULL
THP-1	NULL
(	NULL
monocytic	NULL
)	NULL
cells	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
Mono	NULL
Mac	NULL
6	NULL
(	NULL
monocytic	NULL
)	NULL
cells	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
9	NULL
)	NULL
,	NULL
HeLa	NULL
(	NULL
epithelioid	NULL
)	NULL
cells	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
Jurkat	NULL
(	NULL
T-lymphoid	NULL
)	NULL
cells	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
BJA-B	NULL
(	NULL
B-lymphoid	NULL
)	NULL
cells	NULL
{	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
U937	NULL
(	NULL
monocytic	NULL
)	NULL
cells	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
,	NULL
and	NULL
REX	NULL
(	NULL
T-lymphoid	NULL
)	NULL
cells	NULL
(	NULL
lane	NULL
10	NULL
)	NULL
.	NULL

Lanes	NULL
1	NULL
to	NULL
8	NULL
and	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
are	NULL
from	NULL
two	NULL
independent	NULL
but	NULL
similar	NULL
experiments	NULL
.	NULL

A	NULL
single-stranded	NULL
(	NULL
coding-strand	NULL
)	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
oligonucleotide	NULL
extending	NULL
from	NULL
bp	NULL
-88	NULL
to	NULL
-59	NULL
was	NULL
end	NULL
labeled	NULL
and	NULL
incubated	NULL
with	NULL
10	NULL
jg	NULL
of	NULL
nuclear	NULL
protein	NULL
prepared	NULL
from	NULL
U937	NULL
cells	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

T	NULL
,	NULL
top	NULL
of	NULL
the	NULL
gel	NULL
;	NULL
F	NULL
,	NULL
position	NULL
of	NULL
migration	NULL
of	NULL
the	NULL
free	NULL
oligonucleotide	NULL
.	NULL

Arrows	NULL
indicate	NULL
two	NULL
bands	NULL
shifted	NULL
by	NULL
tissue-specific	NULL
proteins	NULL
(	NULL
Mono	NULL
A	NULL
and	NULL
Mono	NULL
B	NULL
)	NULL
.	NULL

The	NULL
unlabeled	NULL
arrows	NULL
on	NULL
the	NULL
left	NULL
side	NULL
correspond	NULL
to	NULL
the	NULL
positions	NULL
of	NULL
two	NULL
bands	NULL
shifted	NULL
with	NULL
single-stranded	NULL
oligonucleotide	NULL
.	NULL

2	NULL
3	NULL
4	NULL
5	NULL
ence	NULL
30	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Region	NULL
II	NULL
was	NULL
protected	NULL
by	NULL
nuclear	NULL
proteins	NULL
from	NULL
Mono	NULL
Mac	NULL
6	NULL
and	NULL
U937	NULL
.	NULL

The	NULL
nuclear	NULL
extract	NULL
from	NULL
HeLa	NULL
cells	NULL
did	NULL
not	NULL
show	NULL
any	NULL
protection	NULL
of	NULL
the	NULL
coding-strand-labeled	NULL
DNA	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

With	NULL
the	NULL
noncoding-strand-labeled	NULL
DNA	NULL
probe	NULL
,	NULL
nuclear	NULL
extract	NULL
from	NULL
HeLa	NULL
cells	NULL
generated	NULL
a	NULL
DNase	NULL
I-hypersensitive	NULL
band	NULL
at	NULL
bp	NULL
-93	NULL
similar	NULL
to	NULL
that	NULL
formed	NULL
by	NULL
nuclear	NULL
extracts	NULL
from	NULL
monocytic	NULL
cell	NULL
lines	NULL
U937	NULL
and	NULL
Mono	NULL
Mac	NULL
6	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
there	NULL
was	NULL
a	NULL
decrease	NULL
of	NULL
DNase	NULL
I	NULL
sensitivity	NULL
at	NULL
bp	NULL
-69	NULL
compared	NULL
with	NULL
DNA	NULL
without	NULL
any	NULL
nuclear	NULL
extract	NULL
.	NULL

Region	NULL
III	NULL
is	NULL
protected	NULL
by	NULL
nuclear	NULL
proteins	NULL
from	NULL
each	NULL
type	NULL
of	NULL
cells	NULL
.	NULL

With	NULL
DNase	NULL
I	NULL
footprinting	NULL
analysis	NULL
,	NULL
purified	NULL
Spl	NULL
gave	NULL
a	NULL
strong	NULL
protection	NULL
in	NULL
region	NULL
III	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Because	NULL
the	NULL
protection	NULL
at	NULL
region	NULL
II	NULL
appeared	NULL
to	NULL
be	NULL
specific	NULL
for	NULL
monocytic	NULL
cells	NULL
,	NULL
EMSA	NULL
was	NULL
used	NULL
to	NULL
further	NULL
study	NULL
the	NULL
tissue	NULL
distribution	NULL
of	NULL
the	NULL
factor	NULL
or	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
that	NULL
bind	NULL
to	NULL
these	NULL
sequences	NULL
.	NULL

A	NULL
*Â°P-labeled	NULL
double-stranded	NULL
oligonucleotide	NULL
extending	NULL
from	NULL
bp	NULL
-88	NULL
to	NULL
-59	NULL
was	NULL
used	NULL
as	NULL
the	NULL
probe	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
two	NULL
major	NULL
shifted	NULL
bands	NULL
were	NULL
detected	NULL
with	NULL
nuclear	NULL
proteins	NULL
from	NULL
monocytic	NULL
THP-1	NULL
,	NULL
Mono	NULL
Mac	NULL
6	NULL
,	NULL
and	NULL
U937	NULL
cells	NULL
but	NULL
not	NULL
with	NULL
nuclear	NULL
proteins	NULL
from	NULL
a	NULL
number	NULL
of	NULL
nonmonocytic	NULL
cell	NULL
types	NULL
,	NULL
including	NULL
lymphoid	NULL
Jurkat	NULL
(	NULL
T	NULL
)	NULL
and	NULL
BJA-B	NULL
(	NULL
B	NULL
)	NULL
leukemia	NULL
cells	NULL
and	NULL
epithelial	NULL
HeLa	NULL
carcinoma	NULL
cells	NULL
.	NULL

In	NULL
these	NULL
latter	NULL
three	NULL
nonmonocytic	NULL
cell	NULL
types	NULL
,	NULL
very	NULL
faint	NULL
levels	NULL
of	NULL
the	NULL
faster-migrating	NULL
complex	NULL
can	NULL
be	NULL
observed	NULL
upon	NULL
overexposure	NULL
of	NULL
the	NULL
autoradiogram	NULL
.	NULL

Nuclear	NULL
protein	NULL
from	NULL
the	NULL
early	NULL
T-cell	NULL
line	NULL
REX	NULL
contained	NULL
significant	NULL
amounts	NULL
of	NULL
the	NULL
faster-migrating	NULL
shifted	NULL
band	NULL
.	NULL

We	NULL
have	NULL
named	NULL
the	NULL
slower-migrating	NULL
complex	NULL
Mono	NULL
A	NULL
and	NULL
the	NULL
faster-migrating	NULL
complex	NULL
Mono	NULL
B	NULL
.	NULL

There	NULL
were	NULL
two	NULL
faster-migrating	NULL
nonspecific	NULL
bands	NULL
that	NULL
were	NULL
also	NULL
evident	NULL
when	NULL
a	NULL
single-stranded	NULL
oligonucleotide	NULL
was	NULL
used	NULL
as	NULL
the	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

CSF-1	NULL
RECEPTOR	NULL
MONOCYTIC	NULL
REGULATORY	NULL
ELEMENT	NULL
8089	NULL
Mutations	NULL
in	NULL
region	NULL
II	NULL
abolish	NULL
binding	NULL
of	NULL
factors	NULL
Mono	NULL
A	NULL
and	NULL
Mono	NULL
B	NULL
to	NULL
region	NULL
IL	NULL
.	NULL

To	NULL
further	NULL
study	NULL
the	NULL
interaction	NULL
of	NULL
monocytic	NULL
nuclear	NULL
proteins	NULL
with	NULL
region	NULL
II	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
,	NULL
specific	NULL
mutations	NULL
were	NULL
programmed	NULL
into	NULL
region	NULL
II	NULL
oligonucleotides	NULL
and	NULL
tested	NULL
for	NULL
the	NULL
ability	NULL
to	NULL
compete	NULL
for	NULL
the	NULL
Mono	NULL
A-	NULL
and	NULL
Mono	NULL
B-binding	NULL
activities	NULL
.	NULL

Particularly	NULL
informative	NULL
mutant	NULL
oligonucleotides	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
together	NULL
with	NULL
competition	NULL
analysis	NULL
of	NULL
mutant	NULL
unlabeled	NULL
oligonucleotides	NULL
for	NULL
binding	NULL
to	NULL
a	NULL
wild-type	NULL
region	NULL
II	NULL
oligonucleotide	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Mutant	NULL
A	NULL
oligonucleotide	NULL
competed	NULL
for	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
Mono	NULL
B	NULL
complex	NULL
but	NULL
not	NULL
the	NULL
Mono	NULL
A	NULL
complex	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
mutant	NULL
B	NULL
oligonucleotide	NULL
competed	NULL
for	NULL
the	NULL
Mono	NULL
A	NULL
complex	NULL
but	NULL
not	NULL
for	NULL
the	NULL
Mono	NULL
B	NULL
complex	NULL
.	NULL

These	NULL
results	NULL
suggested	NULL
that	NULL
the	NULL
slower-migrating	NULL
monocyte-specific	NULL
complex	NULL
(	NULL
Mono	NULL
A	NULL
)	NULL
was	NULL
formed	NULL
by	NULL
the	NULL
interaction	NULL
of	NULL
nuclear	NULL
protein	NULL
with	NULL
the	NULL
5	NULL
end	NULL
of	NULL
the	NULL
region	NULL
II	NULL
probe	NULL
and	NULL
the	NULL
more	NULL
rapidly	NULL
migrating	NULL
complex	NULL
(	NULL
Mono	NULL
B	NULL
)	NULL
with	NULL
the	NULL
3	NULL
'	NULL
end	NULL
.	NULL

To	NULL
further	NULL
characterize	NULL
the	NULL
interaction	NULL
of	NULL
Mono	NULL
A	NULL
and	NULL
Mono	NULL
B	NULL
components	NULL
with	NULL
region	NULL
II	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
,	NULL
double-stranded	NULL
oligonucleotides	NULL
representing	NULL
the	NULL
5	NULL
'	NULL
(	NULL
oligonucleotide	NULL
A	NULL
,	NULL
bp	NULL
-88	NULL
to	NULL
-73	NULL
)	NULL
and	NULL
3	NULL
'	NULL
(	NULL
oligonucleotide	NULL
B	NULL
,	NULL
bp	NULL
-75	NULL
to	NULL
=59	NULL
)	NULL
sequences	NULL
of	NULL
region	NULL
II	NULL
were	NULL
used	NULL
in	NULL
band	NULL
shift	NULL
competition	NULL
analyses	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
.	NULL

Mono	NULL
A	NULL
specifically	NULL
bound	NULL
to	NULL
5	NULL
'	NULL
region	NULL
II	NULL
oligonucleotide	NULL
A	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
4	NULL
)	NULL
.	NULL

This	NULL
binding	NULL
was	NULL
competed	NULL
for	NULL
by	NULL
unlabeled	NULL
oligonucleotide	NULL
A	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
but	NULL
not	NULL
by	NULL
unlabeled	NULL
oligonucleotide	NULL
B	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Mono	NULL
B	NULL
specifically	NULL
bound	NULL
to	NULL
3	NULL
'	NULL
region	NULL
II	NULL
oligonucleotide	NULL
B	NULL
(	NULL
lanes	NULL
5	NULL
to	NULL
8	NULL
)	NULL
.	NULL

The	NULL
DNA	NULL
sequence	NULL
TGTGGT	NULL
in	NULL
oligonucleotide	NULL
B	NULL
matches	NULL
the	NULL
consensus	NULL
sequence	NULL
for	NULL
nuclear	NULL
factor	NULL
PEBP2/CBF	NULL
binding	NULL
(	NULL
5	NULL
,	NULL
21	NULL
,	NULL
23	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
Mono	NULL
B	NULL
is	NULL
related	NULL
to	NULL
the	NULL
PEBP2/CBF	NULL
family	NULL
,	NULL
EMSA	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
PEBP2/	NULL
CBF-binding	NULL
site	NULL
GGATATCTGTGGTAAGCA	NULL
from	NULL
the	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
virus	NULL
enhancer	NULL
as	NULL
a	NULL
competitor	NULL
(	NULL
27	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
the	NULL
Mono	NULL
B	NULL
complex	NULL
can	NULL
be	NULL
competed	NULL
for	NULL
efficiently	NULL
with	NULL
both	NULL
oligonucleotide	NULL
B	NULL
and	NULL
the	NULL
PEBP2/CBF-binding	NULL
site	NULL
but	NULL
not	NULL
with	NULL
the	NULL
CSF-1	NULL
receptor	NULL
PU.1-binding	NULL
site	NULL
(	NULL
30	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
a	NULL
close	NULL
relationship	NULL
between	NULL
Mono	NULL
B	NULL
and	NULL
PEBP2/CBF	NULL
.	NULL

To	NULL
further	NULL
characterize	NULL
Mono	NULL
B	NULL
,	NULL
antiserum	NULL
raised	NULL
against	NULL
the	NULL
N-terminal	NULL
region	NULL
of	NULL
one	NULL
of	NULL
the	NULL
PEBP2/CBF	NULL
family	NULL
members	NULL
,	NULL
AML1	NULL
(	NULL
7	NULL
)	NULL
,	NULL
was	NULL
used	NULL
in	NULL
the	NULL
EMSA	NULL
analysis	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
we	NULL
detected	NULL
a	NULL
supershifted	NULL
band	NULL
with	NULL
AML1	NULL
antiserum	NULL
but	NULL
not	NULL
with	NULL
antiserum	NULL
against	NULL
nuclear	NULL
factor	NULL
Oct-1	NULL
.	NULL

These	NULL
data	NULL
confirmed	NULL
that	NULL
Mono	NULL
B	NULL
is	NULL
a	NULL
member	NULL
of	NULL
the	NULL
PEBP2/CBF	NULL
family	NULL
and	NULL
identical	NULL
to	NULL
or	NULL
closely	NULL
related	NULL
to	NULL
AMLL1	NULL
.	NULL

Protein-DNA	NULL
interactions	NULL
of	NULL
Mono	NULL
A	NULL
and	NULL
Mone	NULL
B	NULL
with	NULL
region	NULL
II	NULL
sites	NULL
are	NULL
critical	NULL
for	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
activity	NULL
.	NULL

To	NULL
analyze	NULL
the	NULL
function	NULL
of	NULL
the	NULL
protein-DNA	NULL
interactions	NULL
in	NULL
region	NULL
II	NULL
,	NULL
specific	NULL
mutations	NULL
were	NULL
generated	NULL
in	NULL
this	NULL
region	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
luciferase	NULL
construct	NULL
pM-CSF-R-luc	NULL
with	NULL
the	NULL
sequences	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
-416	NULL
to	NULL
+71	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
,	NULL
to	NULL
generate	NULL
pM-CSF-R	NULL
(	NULL
MA	NULL
)	NULL
-lue	NULL
and	NULL
pM-CSF-R	NULL
(	NULL
MB	NULL
)	NULL
-luc	NULL
.	NULL

pM-CSF-R	NULL
(	NULL
MA	NULL
)	NULL
-luec	NULL
and	NULL
pM-CSF-R	NULL
(	NULL
MB	NULL
)	NULL
-luc	NULL
contain	NULL
mutations	NULL
in	NULL
the	NULL
binding	NULL
sites	NULL
for	NULL
Mono	NULL
A	NULL
and	NULL
Mono	NULL
B	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Results	NULL
of	NULL
competion	NULL
experiments	NULL
with	NULL
mutant	NULL
A	NULL
and	NULL
mutant	NULL
B	NULL
oligonucleotides	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
indicated	NULL
that	NULL
mutant	NULL
A	NULL
no	NULL
longer	NULL
bound	NULL
Mono	NULL
A	NULL
but	NULL
did	NULL
not	NULL
affect	NULL
Mono	NULL
B	NULL
binding	NULL
,	NULL
and	NULL
mutant	NULL
B	NULL
affected	NULL
only	NULL
the	NULL
binding	NULL
of	NULL
Mono	NULL
B	NULL
.	NULL

To	NULL
further	NULL
confirm	NULL
that	NULL
these	NULL
mutations	NULL
did	NULL
not	NULL
generate	NULL
any	NULL
new	NULL
interactions	NULL
with	NULL
other	NULL
nuclear	NULL
factors	NULL
,	NULL
EMSA	NULL
was	NULL
performed	NULL
with	NULL
either	NULL
mutant	NULL
A	NULL
or	NULL
mutant	NULL
B	NULL
as	NULL
a	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

Mutant	NULL
A	NULL
probe	NULL
only	NULL
generated	NULL
a	NULL
Mono	NULL
B	NULL
complex	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
which	NULL
could	NULL
be	NULL
abolished	NULL
either	NULL
by	NULL
mutant	NULL
A	NULL
or	NULL
wild-type	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

The	NULL
mutant	NULL
B	NULL
probe	NULL
generated	NULL
only	NULL
a	NULL
Mono	NULL
A	NULL
A	NULL
-88	NULL
419	NULL
C	NULL
WILD	NULL
TYPE	NULL
TCGACAAGATTTCCAAACTCTGTGGTTGCCTTec	NULL
GTTCTAAAGGTTTGAGACACCAACGGAACGAGCT	NULL
Mutant	NULL
A	NULL
Oligo	NULL
A	NULL
Oligo	NULL
B	NULL
Probe	NULL
:	NULL
bp	NULL
-88	NULL
to	NULL
-73	NULL
-	NULL
bp	NULL
-75	NULL
to	NULL
-59	NULL
Mutant	NULL
B	NULL
TCGACAAGATTTCCAAACTCTETAAGGTACCTGC	NULL
Mono	NULL
Mac	NULL
6	NULL
NE	NULL
:	NULL
-o	NULL
$	NULL
oto	NULL
oo+	NULL
a	NULL
p	NULL
pup	NULL
GTTCTAAAGGTTTGAGAGATTCCATGGACGAGCT	NULL
Compe	NULL
iitor	NULL
:	NULL
0	NULL
0	NULL
B	NULL
A	NULL
0	NULL
0	NULL
B	NULL
A	NULL
wh	NULL
ily	NULL
Â«	NULL
16	NULL
%	NULL
,	NULL
Mond	NULL
A	NULL
Â«	NULL
-==	NULL
Â»	NULL
Mono	NULL
B	NULL
-	NULL
>	NULL
B	NULL
Lane	NULL
:	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
Competitors	NULL
:	NULL
-	NULL
Wild	NULL
Type	NULL
Mutant	NULL
A	NULL
Mutant	NULL
B	NULL
PU.1	NULL
Site	NULL
F	NULL
NC	NULL
___	NULL
--	NULL
of	NULL
-_-	NULL
Mono	NULL
A	NULL
--	NULL
|	NULL
UG	NULL
Gad	NULL
wed	NULL
man	NULL
Mono	NULL
B	NULL
--	NULL
-	NULL
|	NULL
i	NULL
=	NULL
)	NULL
|	NULL
Lane	NULL
:	NULL
1	NULL
2	NULL
3	NULL
4	NULL
50	NULL
60	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
16	NULL
17	NULL
18	NULL
19	NULL
20	NULL
21	NULL
22	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

EMSA	NULL
analysis	NULL
of	NULL
region	NULL
II	NULL
sequences	NULL
from	NULL
the	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Sequences	NULL
of	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
bp	NULL
-88	NULL
to	NULL
-59	NULL
wild-type	NULL
and	NULL
mutant	NULL
double-stranded	NULL
oligonucleotides	NULL
used	NULL
in	NULL
the	NULL
band	NULL
shift	NULL
(	NULL
panel	NULL
B	NULL
and	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
and	NULL
transfection	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
experiments	NULL
.	NULL

The	NULL
shaded	NULL
boxes	NULL
indicate	NULL
the	NULL
locations	NULL
of	NULL
mutations	NULL
.	NULL

(	NULL
B	NULL
)	NULL
For	NULL
EMSA	NULL
of	NULL
DNA-protein	NULL
interactions	NULL
including	NULL
region	NULL
II	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
,	NULL
radiolabeled	NULL
wild-type	NULL
double-stranded	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
oligonucleotide	NULL
was	NULL
incubated	NULL
with	NULL
5	NULL
wg	NULL
of	NULL
nuclear	NULL
protein	NULL
prepared	NULL
from	NULL
Mono	NULL
Mac	NULL
6	NULL
cells	NULL
.	NULL

The	NULL
following	NULL
unlabeled	NULL
,	NULL
double-stranded	NULL
competitor	NULL
oligonucleotides	NULL
were	NULL
added	NULL
at	NULL
increasing	NULL
(	NULL
5-	NULL
,	NULL
10-	NULL
,	NULL
25-	NULL
,	NULL
50-	NULL
,	NULL
and	NULL
100-fold	NULL
)	NULL
molar	NULL
excess	NULL
over	NULL
probe	NULL
oligonucleotide	NULL
:	NULL
lanes	NULL
3	NULL
to	NULL
7	NULL
,	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
bp	NULL
-88	NULL
to	NULL
-59	NULL
(	NULL
wild	NULL
type	NULL
)	NULL
;	NULL
lanes	NULL
8	NULL
to	NULL
12	NULL
,	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
mutant	NULL
A	NULL
;	NULL
lanes	NULL
13	NULL
to	NULL
17	NULL
,	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
mutant	NULL
B	NULL
;	NULL
lanes	NULL
18	NULL
to	NULL
22	NULL
,	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
bp	NULL
-59	NULL
to	NULL
-30	NULL
(	NULL
PU.1-binding	NULL
site	NULL
)	NULL
.	NULL

In	NULL
lane	NULL
1	NULL
,	NULL
no	NULL
nuclear	NULL
protein	NULL
was	NULL
added	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
;	NULL
in	NULL
lane	NULL
2	NULL
,	NULL
5	NULL
jpg	NULL
of	NULL
nuclear	NULL
protein	NULL
from	NULL
Mono	NULL
Mac	NULL
6	NULL
cells	NULL
was	NULL
added	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
competitor	NULL
.	NULL

The	NULL
arrows	NULL
marked	NULL
Mono	NULL
A	NULL
and	NULL
Mono	NULL
B	NULL
mark	NULL
the	NULL
specific	NULL
complexes	NULL
binding	NULL
to	NULL
region	NULL
II	NULL
in	NULL
monocytic	NULL
cells	NULL
.	NULL

(	NULL
C	NULL
)	NULL
EMSA	NULL
of	NULL
the	NULL
interactions	NULL
of	NULL
the	NULL
upstream	NULL
(	NULL
5	NULL
)	NULL
and	NULL
downstream	NULL
(	NULL
3	NULL
'	NULL
)	NULL
sequences	NULL
of	NULL
region	NULL
II	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
with	NULL
monocytic	NULL
proteins	NULL
.	NULL

Double-stranded	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
oligonucleotide	NULL
A	NULL
,	NULL
extending	NULL
from	NULL
bp	NULL
-88	NULL
to	NULL
-73	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
4	NULL
)	NULL
,	NULL
or	NULL
oligonucleotide	NULL
B	NULL
,	NULL
extending	NULL
from	NULL
bp	NULL
-75	NULL
to	NULL
-59	NULL
(	NULL
lanes	NULL
5	NULL
to	NULL
8	NULL
)	NULL
,	NULL
was	NULL
labeled	NULL
and	NULL
incubated	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
5	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
lanes	NULL
2	NULL
to	NULL
4	NULL
and	NULL
6	NULL
to	NULL
8	NULL
)	NULL
of	NULL
5	NULL
ug	NULL
of	NULL
nuclear	NULL
protein	NULL
prepared	NULL
from	NULL
Mono	NULL
Mac	NULL
6	NULL
cells	NULL
.	NULL

Lanes	NULL
3	NULL
and	NULL
7	NULL
also	NULL
contain	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
oligonucleotide	NULL
B	NULL
in	NULL
the	NULL
binding	NULL
reaction	NULL
mixture	NULL
.	NULL

Lanes	NULL
4	NULL
and	NULL
8	NULL
have	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
oligonucleotide	NULL
A	NULL
in	NULL
the	NULL
binding	NULL
reaction	NULL
mixture	NULL
.	NULL

Other	NULL
symbols	NULL
are	NULL
as	NULL
described	NULL
for	NULL
panel	NULL
B	NULL
.	NULL

8090	NULL
Vou	NULL
.	NULL

14	NULL
,	NULL
1994	NULL
A	NULL
C	NULL
rae	NULL
Oligo	NULL
B	NULL
PEBP2	NULL
PU.1	NULL
'ompetitor	NULL
:	NULL
-	NULL
-	NULL
z	NULL
Mono	NULL
Mac	NULL
6NE	NULL
:	NULL
-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
Antiserum	NULL
:	NULL
Competitor	NULL
:	NULL
THP-1	NULL
NE	NULL
:	NULL
Supershift	NULL
Mono	NULL
B	NULL
Lane	NULL
:	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Mono	NULL
B	NULL
is	NULL
related	NULL
to	NULL
PEBP2/CBF	NULL
.	NULL

(	NULL
A	NULL
)	NULL
A	NULL
double-stranded	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
oligonucleotide	NULL
extending	NULL
from	NULL
bp	NULL
-75	NULL
to	NULL
-59	NULL
was	NULL
labeled	NULL
and	NULL
incubated	NULL
without	NULL
any	NULL
nuclear	NULL
protein	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
with	NULL
5	NULL
mg	NULL
of	NULL
nuclear	NULL
protein	NULL
prepared	NULL
from	NULL
monocytic	NULL
Mono	NULL
Mac	NULL
6	NULL
cells	NULL
(	NULL
lanes	NULL
2	NULL
to	NULL
7	NULL
)	NULL
.	NULL

The	NULL
following	NULL
unlabeled	NULL
,	NULL
double-stranded	NULL
competitor	NULL
oligonucleotides	NULL
were	NULL
added	NULL
:	NULL
lane	NULL
2	NULL
,	NULL
no	NULL
added	NULL
competitor	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
10-fold	NULL
molar	NULL
excess	NULL
self	NULL
(	NULL
oligonucleotide	NULL
B	NULL
)	NULL
competitor	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
50-fold	NULL
molar	NULL
excess	NULL
of	NULL
self	NULL
competitor	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
consensus	NULL
PEBP2/CBF	NULL
site	NULL
from	NULL
the	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
virus	NULL
enhancer	NULL
(	NULL
5	NULL
'	NULL
GGATATCTGTGGTAAGCA	NULL
3	NULL
'	NULL
)	NULL
(	NULL
27	NULL
)	NULL
,	NULL
10-fold	NULL
molar	NULL
excess	NULL
;	NULL
lane	NULL
6	NULL
,	NULL
PEBP2/CBF	NULL
competitor	NULL
,	NULL
50-fold	NULL
molar	NULL
excess	NULL
;	NULL
lane	NULL
7	NULL
,	NULL
CSF-1	NULL
receptor	NULL
PU.1	NULL
site	NULL
,	NULL
50	NULL
fold	NULL
molar	NULL
excess	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
CSF-1	NULL
receptor	NULL
oligonucleotide	NULL
used	NULL
for	NULL
panel	NULL
A	NULL
was	NULL
labeled	NULL
and	NULL
incubated	NULL
without	NULL
any	NULL
nuclear	NULL
protein	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
with	NULL
5	NULL
mg	NULL
of	NULL
nuclear	NULL
protein	NULL
prepared	NULL
from	NULL
monocytic	NULL
THP-1	NULL
cells	NULL
(	NULL
lanes	NULL
2	NULL
to	NULL
5	NULL
)	NULL
.	NULL

In	NULL
lane	NULL
3	NULL
,	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
self	NULL
(	NULL
oligonucleotide	NULL
B	NULL
)	NULL
competitor	NULL
oligonucleotide	NULL
was	NULL
added	NULL
.	NULL

In	NULL
lane	NULL
4	NULL
,	NULL
1	NULL
pl	NULL
of	NULL
an	NULL
anti-AML1	NULL
antiserum	NULL
(	NULL
7	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
extract	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
labeled	NULL
probe	NULL
.	NULL

In	NULL
lane	NULL
5	NULL
,	NULL
1	NULL
wl	NULL
of	NULL
an	NULL
anti-Oct-1	NULL
antiserum	NULL
was	NULL
added	NULL
.	NULL

CSF-1	NULL
RECEPTOR	NULL
MONOCYTIC	NULL
REGULATORY	NULL
ELEMENT	NULL
8091	NULL
complex	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
,	NULL
which	NULL
could	NULL
be	NULL
abolished	NULL
by	NULL
either	NULL
mutant	NULL
B	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
or	NULL
wild-type	NULL
(	NULL
lane	NULL
9	NULL
)	NULL
oligonucleotide	NULL
.	NULL

Transient	NULL
transfection	NULL
experiments	NULL
showed	NULL
that	NULL
each	NULL
mutation	NULL
decreased	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
activity	NULL
to	NULL
13	NULL
%	NULL
of	NULL
the	NULL
wild-type	NULL
level	NULL
in	NULL
monocytic	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

These	NULL
mutations	NULL
did	NULL
not	NULL
affect	NULL
promoter	NULL
activity	NULL
in	NULL
nonmonocytic	NULL
Hela	NULL
and	NULL
REX	NULL
cells	NULL
,	NULL
although	NULL
the	NULL
reporter	NULL
luciferase	NULL
activity	NULL
was	NULL
still	NULL
more	NULL
than	NULL
10	NULL
times	NULL
higher	NULL
than	NULL
the	NULL
promoterless	NULL
luciferase	NULL
construct	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
region	NULL
II	NULL
and	NULL
its	NULL
binding	NULL
proteins	NULL
are	NULL
essential	NULL
for	NULL
tissue-specific	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
activity	NULL
.	NULL

As	NULL
we	NULL
reported	NULL
previously	NULL
,	NULL
the	NULL
myeloid	NULL
cell-	NULL
and	NULL
B-cell-specific	NULL
transcription	NULL
factor	NULL
PU.1	NULL
binds	NULL
to	NULL
the	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
at	NULL
bp	NULL
-51	NULL
to	NULL
-33	NULL
(	NULL
region	NULL
I	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
(	NULL
30	NULL
)	NULL
.	NULL

The	NULL
mutation	NULL
at	NULL
region	NULL
I	NULL
abolishes	NULL
PU.1	NULL
binding	NULL
and	NULL
decreases	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
activity	NULL
in	NULL
a	NULL
tissue-specific	NULL
manner	NULL
to	NULL
16	NULL
%	NULL
of	NULL
wild-type	NULL
promoter	NULL
activity	NULL
.	NULL

To	NULL
understand	NULL
the	NULL
contributions	NULL
of	NULL
PU.1	NULL
and	NULL
proteins	NULL
binding	NULL
to	NULL
region	NULL
II	NULL
to	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
activity	NULL
,	NULL
deletion	NULL
construct	NULL
pMCSF-R	NULL
(	NULL
DD	NULL
)	NULL
-luc	NULL
,	NULL
containing	NULL
a	NULL
bp	NULL
-86	NULL
to	NULL
-37	NULL
deletion	NULL
,	NULL
was	NULL
used	NULL
in	NULL
transient	NULL
transfections	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
this	NULL
deleted	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
construct	NULL
lost	NULL
almost	NULL
all	NULL
activity	NULL
in	NULL
monocytic	NULL
cells	NULL
.	NULL

In	NULL
another	NULL
set	NULL
of	NULL
four	NULL
independent	NULL
experiments	NULL
,	NULL
a	NULL
deletion	NULL
from	NULL
bp	NULL
-86	NULL
to	NULL
-62	NULL
,	NULL
removing	NULL
the	NULL
Mono	NULL
A-	NULL
and	NULL
Mono	NULL
B-binding	NULL
sites	NULL
,	NULL
reduced	NULL
promoter	NULL
activity	NULL
16	NULL
%	NULL
*+	NULL
5	NULL
%	NULL
(	NULL
standard	NULL
devia-tion	NULL
,	NULL
comparable	NULL
to	NULL
that	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6B	NULL
for	NULL
either	NULL
mutant	NULL
A	NULL
(	NULL
13	NULL
%	NULL
)	NULL
or	NULL
mutant	NULL
B	NULL
(	NULL
13	NULL
%	NULL
)	NULL
alone	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
the	NULL
results	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
demonstrate	NULL
that	NULL
both	NULL
region	NULL
II	NULL
proteins	NULL
and	NULL
PU.1	NULL
are	NULL
important	NULL
for	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
activity	NULL
.	NULL

CSF-1	NULL
receptor	NULL
promoter	NULL
region	NULL
II	NULL
functions	NULL
as	NULL
a	NULL
tissue-specific	NULL
enhancer	NULL
.	NULL

To	NULL
further	NULL
demonstrate	NULL
the	NULL
role	NULL
of	NULL
region	NULL
II-specific	NULL
factors	NULL
for	NULL
promoter	NULL
activity	NULL
,	NULL
these	NULL
sequences	NULL
were	NULL
multimerized	NULL
and	NULL
inserted	NULL
upstream	NULL
of	NULL
a	NULL
basal	NULL
thymidine	NULL
kinase	NULL
promoter-luciferase	NULL
construct	NULL
,	NULL
pT8l-luc	NULL
,	NULL
to	NULL
form	NULL
p	NULL
(	NULL
Mono	NULL
)	NULL
,	NULL
T81-luc	NULL
,	NULL
p	NULL
(	NULL
Mono	NULL
)	NULL
,	NULL
T81-luc	NULL
,	NULL
and	NULL
p	NULL
(	NULL
Mono	NULL
)	NULL
sg	NULL
T81	NULL
-luc	NULL
.	NULL

These	NULL
constructs	NULL
and	NULL
the	NULL
parent	NULL
pT8l-luc	NULL
construct	NULL
were	NULL
transiently	NULL
transfected	NULL
into	NULL
monocytic	NULL
Mono	NULL
Mac	NULL
6	NULL
cells	NULL
and	NULL
nonmonocytic	NULL
REX	NULL
and	NULL
HeLa	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Promoter	NULL
activity	NULL
increased	NULL
20-	NULL
to	NULL
30-fold	NULL
when	NULL
multimerized	NULL
region	NULL
II	NULL
constructs	NULL
were	NULL
transfected	NULL
into	NULL
Mono	NULL
Mac	NULL
6	NULL
cells	NULL
,	NULL
while	NULL
promoter	NULL
activity	NULL
in	NULL
nonmonocytic	NULL
cells	NULL
remained	NULL
at	NULL
near	NULL
baseline	NULL
levels	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
when	NULL
the	NULL
orientation	NULL
of	NULL
the	NULL
hexamer	NULL
was	NULL
reversed	NULL
in	NULL
p	NULL
(	NULL
Mono	NULL
)	NULL
,	NULL
g	NULL
TK81-luc	NULL
,	NULL
region	NULL
II	NULL
had	NULL
slightly	NULL
greater	NULL
ability	NULL
to	NULL
act	NULL
as	NULL
an	NULL
activator	NULL
in	NULL
monocytic	NULL
cells	NULL
,	NULL
indicating	NULL
orientation-independent	NULL
activity	NULL
mediated	NULL
through	NULL
these	NULL
sequences	NULL
.	NULL

DISCUSSION	NULL
Previous	NULL
studies	NULL
have	NULL
indicated	NULL
that	NULL
the	NULL
monocyte/macro-phage	NULL
specificity	NULL
of	NULL
the	NULL
human	NULL
CSF-1	NULL
receptor	NULL
is	NULL
mediated	NULL
by	NULL
transcriptional	NULL
mechanisms	NULL
and	NULL
that	NULL
as	NULL
little	NULL
as	NULL
416	NULL
bp	NULL
of	NULL
the	NULL
promoter	NULL
can	NULL
direct	NULL
monocyte-specific	NULL
expression	NULL
of	NULL
reporter	NULL
genes	NULL
in	NULL
transient	NULL
transfections	NULL
of	NULL
human	NULL
cell	NULL
lines	NULL
(	NULL
18	NULL
,	NULL
30	NULL
)	NULL
.	NULL

In	NULL
these	NULL
studies	NULL
,	NULL
we	NULL
identified	NULL
a	NULL
functional	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
macrophage	NULL
factor	NULL
PU.1	NULL
,	NULL
which	NULL
was	NULL
shown	NULL
to	NULL
play	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
macrophage-specific	NULL
expression	NULL
of	NULL
the	NULL
promoter	NULL
(	NULL
30	NULL
)	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
extended	NULL
these	NULL
studies	NULL
to	NULL
examine	NULL
what	NULL
other	NULL
factors	NULL
might	NULL
regulate	NULL
this	NULL
promoter	NULL
.	NULL

Deletion	NULL
studies	NULL
demonstrated	NULL
that	NULL
as	NULL
little	NULL
as	NULL
85	NULL
bp	NULL
of	NULL
upstream	NULL
sequence	NULL
directed	NULL
nearly	NULL
threefold-higher	NULL
levels	NULL
of	NULL
promoter	NULL
activity	NULL
with	NULL
nearly	NULL
twofold-greater	NULL
relative	NULL
specificity	NULL
as	NULL
compared	NULL
with	NULL
results	NULL
with	NULL
a	NULL
larger	NULL
480-bp	NULL
promoter	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
the	NULL
presence	NULL
of	NULL
negative	NULL
regulatory	NULL
elements	NULL
with	NULL
some	NULL
degree	NULL
of	NULL
cell	NULL
type	NULL
specificity	NULL
and	NULL
,	NULL
importantly	NULL
,	NULL
that	NULL
the	NULL
major	NULL
positive	NULL
factors	NULL
determining	NULL
macrophage	NULL
specificity	NULL
act	NULL
on	NULL
a	NULL
limited	NULL
85-bp	NULL
region	NULL
.	NULL

What	NULL
transcription	NULL
factors	NULL
interact	NULL
with	NULL
this	NULL
85	NULL
bp	NULL
region	NULL
?	NULL

8092	NULL
ZHANG	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
Probe	NULL
:	NULL
Mutant	NULL
A	NULL
Mutant	NULL
B	NULL
THP-1	NULL
NE	NULL
:	NULL
-	NULL
+	NULL
+++	NULL
~o	NULL
ko	NULL
+o	NULL
o+	NULL
+	NULL
Competitor	NULL
:	NULL
-	NULL
0	NULL
0	NULL
MA	NULL
W	NULL
MB	NULL
0	NULL
0	NULL
MB	NULL
w	NULL
Ma	NULL
Mono	NULL
A	NULL
Mono	NULL
B	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

FIG	NULL
.	NULL

6	NULL
.	NULL

Nuclear	NULL
factor	NULL
Mono	NULL
A	NULL
and	NULL
Mono	NULL
B	NULL
are	NULL
critical	NULL
for	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
activity	NULL
.	NULL

(	NULL
A	NULL
)	NULL
To	NULL
demonstrate	NULL
which	NULL
complexes	NULL
bind	NULL
to	NULL
the	NULL
mutant	NULL
oligonucleotides	NULL
used	NULL
in	NULL
the	NULL
functional	NULL
studies	NULL
in	NULL
panel	NULL
B	NULL
,	NULL
double-stranded	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
mutant	NULL
A	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
5	NULL
)	NULL
and	NULL
mutant	NULL
B	NULL
(	NULL
lanes	NULL
6	NULL
to	NULL
10	NULL
)	NULL
oligonucleotides	NULL
were	NULL
labeled	NULL
and	NULL
incubated	NULL
without	NULL
any	NULL
nuclear	NULL
protein	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
6	NULL
)	NULL
or	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
nuclear	NULL
protein	NULL
prepared	NULL
from	NULL
monocytic	NULL
THP-1	NULL
cells	NULL
(	NULL
lanes	NULL
2	NULL
to	NULL
5	NULL
and	NULL
7	NULL
to	NULL
10	NULL
)	NULL
.	NULL

The	NULL
following	NULL
unlabeled	NULL
,	NULL
double-stranded	NULL
competitor	NULL
oligonucleotides	NULL
were	NULL
added	NULL
at	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
over	NULL
probe	NULL
oligonucleotide	NULL
:	NULL
lanes	NULL
3	NULL
and	NULL
10	NULL
,	NULL
mutant	NULL
A	NULL
;	NULL
lanes	NULL
4	NULL
and	NULL
9	NULL
,	NULL
wild-type	NULL
bp	NULL
-88	NULL
to	NULL
-59	NULL
oligonucleotide	NULL
;	NULL
lanes	NULL
5	NULL
and	NULL
8	NULL
,	NULL
mutant	NULL
B	NULL
oligonucleotide	NULL
.	NULL

Sequences	NULL
of	NULL
the	NULL
wild-type	NULL
,	NULL
mutant	NULL
A	NULL
,	NULL
and	NULL
mutant	NULL
B	NULL
oligonucleotides	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4A	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
wild-type	NULL
CSF-1	NULL
receptor	NULL
promoter-luciferase	NULL
construct	NULL
pM-CSF-R-luc	NULL
,	NULL
the	NULL
mutant	NULL
constructs	NULL
pM-CSF-R	NULL
(	NULL
MA	NULL
)	NULL
-lue	NULL
and	NULL
pM-CSF-R	NULL
(	NULL
MB	NULL
)	NULL
-luc	NULL
,	NULL
and	NULL
the	NULL
region	NULL
II	NULL
and	NULL
region	NULL
I	NULL
(	NULL
PU.1-binding	NULL
site	NULL
)	NULL
double-deleted	NULL
construct	NULL
pM-CSF-R	NULL
(	NULL
DD	NULL
)	NULL
-luc	NULL
were	NULL
transfected	NULL
into	NULL
the	NULL
human	NULL
monocytic	NULL
cell	NULL
line	NULL
Mono	NULL
Mac	NULL
6	NULL
and	NULL
nonmonocytic	NULL
cell	NULL
lines	NULL
REX	NULL
(	NULL
T	NULL
cell	NULL
)	NULL
and	NULL
HeLa	NULL
.	NULL

The	NULL
average	NULL
promoter	NULL
activities	NULL
were	NULL
generated	NULL
from	NULL
three	NULL
separate	NULL
experiments	NULL
for	NULL
each	NULL
cell	NULL
line	NULL
.	NULL

The	NULL
standard	NULL
deviation	NULL
of	NULL
the	NULL
mean	NULL
is	NULL
indicated	NULL
by	NULL
the	NULL
error	NULL
bars	NULL
.	NULL

Luciferase	NULL
activities	NULL
(	NULL
expressed	NULL
in	NULL
relative	NULL
light	NULL
units	NULL
[	NULL
RLU	NULL
]	NULL
)	NULL
are	NULL
normalized	NULL
for	NULL
transfection	NULL
efficiency	NULL
with	NULL
the	NULL
cotransfected	NULL
growth	NULL
hormone	NULL
plasmid	NULL
RSV-hGH	NULL
.	NULL

Promoter	NULL
Activity	NULL
B	NULL
(	NULL
RLU/ng	NULL
Growth	NULL
Hormone	NULL
)	NULL
Mono	NULL
Mac	NULL
6	NULL
REX	NULL
HeLa	NULL
pM-CSF-R-lue	NULL
37547	NULL
+	NULL
9793	NULL
4197	NULL
+	NULL
2214	NULL
1591	NULL
+	NULL
980	NULL
pM-CSF-R	NULL
(	NULL
MA	NULL
)	NULL
-lue	NULL
4845	NULL
+719	NULL
5533	NULL
+	NULL
1684	NULL
2108	NULL
+	NULL
241	NULL
pM-CSF-R	NULL
(	NULL
MB	NULL
)	NULL
'1UC	NULL
I	NULL
Mono	NULL
Mac	NULL
6	NULL
5126	NULL
+	NULL
616	NULL
3979	NULL
+	NULL
2028	NULL
1422	NULL
+	NULL
422	NULL
Â§	NULL
rex	NULL
pM-CSF-R	NULL
(	NULL
DD	NULL
)	NULL
-lue	NULL
PA	NULL
neua	NULL
1388	NULL
+	NULL
360	NULL
4279	NULL
+	NULL
1676	NULL
2459	NULL
+	NULL
145	NULL
I	NULL
I	NULL
T	NULL
I	NULL
I	NULL
0	NULL
(	NULL
Y	NULL
o	NULL
0	NULL
Sun	NULL
â	NULL
gee	NULL
â	NULL
3	NULL
â	NULL
an	NULL
â	NULL
59Â°	NULL
â	NULL
a	NULL
iS	NULL
,	NULL
Promoter	NULL
Activity	NULL
(	NULL
RLU/ng	NULL
Growth	NULL
Hormone	NULL
)	NULL
DNase	NULL
I	NULL
footprint	NULL
experiments	NULL
revealed	NULL
that	NULL
besides	NULL
the	NULL
PU.1	NULL
site	NULL
at	NULL
bp	NULL
-40	NULL
,	NULL
there	NULL
is	NULL
a	NULL
single	NULL
region	NULL
(	NULL
region	NULL
II	NULL
)	NULL
bound	NULL
by	NULL
factors	NULL
from	NULL
macrophage	NULL
cells	NULL
.	NULL

Further	NULL
analysis	NULL
demonstrated	NULL
at	NULL
least	NULL
two	NULL
distinct	NULL
complexes	NULL
in	NULL
EMSA	NULL
with	NULL
probes	NULL
corresponding	NULL
to	NULL
sequences	NULL
from	NULL
this	NULL
region	NULL
.	NULL

Functional	NULL
studies	NULL
show	NULL
that	NULL
both	NULL
play	NULL
a	NULL
significant	NULL
role	NULL
in	NULL
macrophage	NULL
expression	NULL
of	NULL
the	NULL
promoter	NULL
.	NULL

The	NULL
sequences	NULL
at	NULL
the	NULL
5	NULL
'	NULL
and	NULL
3	NULL
'	NULL
ends	NULL
of	NULL
region	NULL
II	NULL
,	NULL
containing	NULL
the	NULL
binding	NULL
sites	NULL
for	NULL
Mono	NULL
A	NULL
and	NULL
Mono	NULL
B	NULL
,	NULL
respectively	NULL
,	NULL
are	NULL
not	NULL
similar	NULL
,	NULL
suggesting	NULL
that	NULL
these	NULL
two	NULL
complexes	NULL
contain	NULL
different	NULL
DNA-binding	NULL
activities	NULL
and	NULL
are	NULL
not	NULL
simply	NULL
different	NULL
isoforms	NULL
of	NULL
a	NULL
single	NULL
DNA-binding	NULL
activity	NULL
.	NULL

The	NULL
results	NULL
of	NULL
competition	NULL
studies	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
and	NULL
supershift	NULL
experiments	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
indicate	NULL
that	NULL
Mono	NULL
B	NULL
contains	NULL
a	NULL
member	NULL
of	NULL
the	NULL
PEBP2/CBF	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

These	NULL
factors	NULL
consist	NULL
of	NULL
heterdimers	NULL
between	NULL
DNA-binding	NULL
a	NULL
sub-units	NULL
,	NULL
which	NULL
recognize	NULL
the	NULL
consensus	NULL
site	NULL
TGTGGT	NULL
,	NULL
and	NULL
a	NULL
B	NULL
subunit	NULL
which	NULL
does	NULL
not	NULL
bind	NULL
DNA	NULL
directly	NULL
but	NULL
enhances	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
a	NULL
subunit	NULL
(	NULL
26	NULL
,	NULL
27	NULL
)	NULL
.	NULL

Multiple	NULL
Â«	NULL
subunit	NULL
genes	NULL
and	NULL
alternatively	NULL
spliced	NULL
isoforms	NULL
of	NULL
the	NULL
a	NULL
and	NULL
B	NULL
subunits	NULL
have	NULL
been	NULL
detected	NULL
.	NULL

The	NULL
a	NULL
subunits	NULL
include	NULL
a	NULL
Drosophila	NULL
runt	NULL
homology	NULL
domain	NULL
which	NULL
mediates	NULL
DNA	NULL
binding	NULL
and	NULL
protein-protein	NULL
interactions	NULL
.	NULL

One	NULL
of	NULL
the	NULL
human	NULL
a	NULL
genes	NULL
(	NULL
AML1	NULL
)	NULL
is	NULL
located	NULL
at	NULL
the	NULL
breakpoint	NULL
of	NULL
the	NULL
relatively	NULL
common	NULL
translocation	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
(	NULL
q22	NULL
;	NULL
q22	NULL
)	NULL
found	NULL
in	NULL
one	NULL
of	NULL
the	NULL
most	NULL
common	NULL
forms	NULL
of	NULL
FAB	NULL
M2	NULL
AML	NULL
.	NULL

The	NULL
B	NULL
chain	NULL
is	NULL
also	NULL
involved	NULL
in	NULL
a	NULL
chromosome	NULL
translocation	NULL
[	NULL
inv	NULL
(	NULL
16	NULL
)	NULL
(	NULL
p13q22	NULL
)	NULL
]	NULL
associated	NULL
with	NULL
FAB	NULL
M4eo	NULL
AML	NULL
.	NULL

Therefore	NULL
,	NULL
each	NULL
of	NULL
the	NULL
two	NULL
chains	NULL
of	NULL
the	NULL
PEBP2/	NULL
CBF	NULL
heterodimer	NULL
is	NULL
directly	NULL
implicated	NULL
the	NULL
pathogenesis	NULL
of	NULL
VoL	NULL
.	NULL

14	NULL
,	NULL
1994	NULL
CSF-1	NULL
RECEPTOR	NULL
MONOCYTIC	NULL
REGULATORY	NULL
ELEMENT	NULL
8093	NULL
Mono	NULL
Mac	NULL
6	NULL
REX	NULL
Hela	NULL
3	NULL
?	NULL

40	NULL
-	NULL
.	NULL

Mono	NULL
Mac	NULL
6	NULL
's	NULL
M	NULL
TK81-3	NULL
BJ	NULL
rex	NULL
_	NULL
pp	NULL
9	NULL
,	NULL
24	NULL
1.5	NULL
+	NULL
0.3	NULL
1.1	NULL
+0.5	NULL
n	NULL
pTK81-lue	NULL
8	NULL
30	NULL
-	NULL
41	NULL
Hela	NULL
E	NULL
2	NULL
p	NULL
(	NULL
Mono	NULL
)	NULL
gTK81-lue	NULL
fa	NULL
--	NULL
-in	NULL
17.3	NULL
+	NULL
1.2	NULL
0.5	NULL
+	NULL
0.1	NULL
1.0	NULL
+	NULL
0.4	NULL
&	NULL
pTK81-lue	NULL
3	NULL
k-p	NULL
(	NULL
Mono	NULL
)	NULL
ep	NULL
TK81	NULL
-luc	NULL
4	NULL
=	NULL
--	NULL
-	NULL
0	NULL
3174110	NULL
0.8	NULL
+	NULL
0.1	NULL
1.0	NULL
+	NULL
0.1	NULL
3	NULL
pTK81-lue	NULL
Fie	NULL
4X	NULL
6X	NULL
6GX-R	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Enhancer	NULL
activity	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
region	NULL
II	NULL
.	NULL

CSF-1	NULL
receptor	NULL
promoter	NULL
bp	NULL
-88	NULL
to	NULL
-59	NULL
oligonucleotides	NULL
were	NULL
ligated	NULL
head	NULL
to	NULL
tail	NULL
to	NULL
form	NULL
a	NULL
tetramer	NULL
and	NULL
a	NULL
hexamer	NULL
and	NULL
inserted	NULL
in	NULL
front	NULL
of	NULL
the	NULL
herpes	NULL
simplex	NULL
virus	NULL
thymidine	NULL
kinase	NULL
promoter-luciferase	NULL
constructs	NULL
pT81-luc	NULL
to	NULL
form	NULL
p	NULL
(	NULL
Mono	NULL
)	NULL
,	NULL
T81-luc	NULL
,	NULL
p	NULL
(	NULL
Mono	NULL
)	NULL
,	NULL
T81-luc	NULL
,	NULL
and	NULL
p	NULL
(	NULL
Mono	NULL
)	NULL
,	NULL
g	NULL
T81-luc	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

These	NULL
constructs	NULL
were	NULL
transfected	NULL
into	NULL
monocytic	NULL
Mono	NULL
Mac	NULL
6	NULL
cells	NULL
and	NULL
nonmonocytic	NULL
REX	NULL
and	NULL
HeLa	NULL
cells	NULL
.	NULL

The	NULL
average	NULL
promoter	NULL
activities	NULL
were	NULL
generated	NULL
from	NULL
three	NULL
separate	NULL
experiments	NULL
for	NULL
each	NULL
cell	NULL
line	NULL
.	NULL

Luciferase	NULL
activities	NULL
were	NULL
normalized	NULL
for	NULL
transfection	NULL
efficiency	NULL
with	NULL
the	NULL
cotransfected	NULL
growth	NULL
hormone	NULL
plasmid	NULL
RSV-hGH	NULL
.	NULL

Results	NULL
are	NULL
presented	NULL
as	NULL
the	NULL
normalized	NULL
luciferase	NULL
units	NULL
for	NULL
p	NULL
(	NULL
Mono	NULL
)	NULL
,	NULL
T81-luc	NULL
,	NULL
p	NULL
(	NULL
Mono	NULL
)	NULL
,	NULL
T81-luc	NULL
,	NULL
or	NULL
p	NULL
(	NULL
Mono	NULL
)	NULL
,	NULL
g	NULL
T81-luc	NULL
divided	NULL
by	NULL
those	NULL
for	NULL
pT81-luc	NULL
.	NULL

The	NULL
standard	NULL
deviation	NULL
of	NULL
the	NULL
mean	NULL
is	NULL
indicated	NULL
by	NULL
the	NULL
error	NULL
bars	NULL
.	NULL

AML	NULL
.	NULL

As	NULL
has	NULL
been	NULL
recently	NULL
pointed	NULL
out	NULL
(	NULL
11	NULL
)	NULL
,	NULL
the	NULL
fusion	NULL
proteins	NULL
produced	NULL
in	NULL
these	NULL
translocations	NULL
could	NULL
block	NULL
normal	NULL
myeloid	NULL
differentiation	NULL
by	NULL
altering	NULL
normal	NULL
PEBP2/CBF	NULL
func-tion	NULL
,	NULL
which	NULL
serves	NULL
to	NULL
activate	NULL
the	NULL
expression	NULL
of	NULL
at	NULL
least	NULL
two	NULL
important	NULL
myeloid	NULL
target	NULL
genes	NULL
,	NULL
those	NULL
encoding	NULL
myeloperoxidase	NULL
and	NULL
the	NULL
CSF-1	NULL
receptor	NULL
.	NULL

In	NULL
our	NULL
supershift	NULL
studies	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
,	NULL
an	NULL
antiserum	NULL
raised	NULL
against	NULL
the	NULL
17-amino-acid	NULL
N	NULL
terminus	NULL
of	NULL
AML1	NULL
shifted	NULL
only	NULL
a	NULL
fraction	NULL
of	NULL
the	NULL
Mono	NULL
B	NULL
complex	NULL
.	NULL

The	NULL
same	NULL
results	NULL
were	NULL
obtained	NULL
by	NULL
other	NULL
investigators	NULL
(	NULL
7	NULL
,	NULL
11	NULL
)	NULL
.	NULL

This	NULL
serum	NULL
is	NULL
likely	NULL
to	NULL
react	NULL
with	NULL
the	NULL
related	NULL
PEBP2	NULL
Â«	NULL
A	NULL
protein	NULL
and	NULL
perhaps	NULL
other	NULL
family	NULL
members	NULL
as	NULL
well	NULL
.	NULL

The	NULL
unshifted	NULL
Mono	NULL
B	NULL
complex	NULL
could	NULL
consist	NULL
of	NULL
a	NULL
PEBP2/CBF	NULL
Â«	NULL
chain	NULL
with	NULL
an	NULL
amino	NULL
terminus	NULL
not	NULL
recognized	NULL
by	NULL
this	NULL
antiserum	NULL
,	NULL
either	NULL
because	NULL
of	NULL
sequence	NULL
divergence	NULL
or	NULL
because	NULL
the	NULL
epitope	NULL
is	NULL
in	NULL
a	NULL
conformation	NULL
not	NULL
recognized	NULL
by	NULL
the	NULL
antiserum	NULL
.	NULL

Alternatively	NULL
,	NULL
it	NULL
is	NULL
still	NULL
possible	NULL
that	NULL
part	NULL
of	NULL
the	NULL
unshifted	NULL
Mono	NULL
B	NULL
complex	NULL
is	NULL
formed	NULL
by	NULL
an	NULL
unrelated	NULL
protein	NULL
.	NULL

The	NULL
identity	NULL
of	NULL
the	NULL
Mono	NULL
A	NULL
factor	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

Mono	NULL
A	NULL
can	NULL
bind	NULL
independently	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
Mono	NULL
B	NULL
site	NULL
,	NULL
but	NULL
our	NULL
competition	NULL
studies	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
show	NULL
that	NULL
the	NULL
mutant	NULL
A	NULL
oligonucleotide	NULL
(	NULL
containing	NULL
an	NULL
intact	NULL
Mono	NULL
B	NULL
site	NULL
)	NULL
variably	NULL
and	NULL
partially	NULL
competes	NULL
for	NULL
Mono	NULL
A	NULL
binding	NULL
,	NULL
suggesting	NULL
cooperativity	NULL
in	NULL
binding	NULL
or	NULL
some	NULL
type	NULL
of	NULL
similarity	NULL
between	NULL
proteins	NULL
of	NULL
the	NULL
Mono	NULL
A	NULL
and	NULL
Mono	NULL
B	NULL
complexes	NULL
.	NULL

PEBP2/CBF	NULL
has	NULL
been	NULL
described	NULL
to	NULL
interact	NULL
with	NULL
either	NULL
the	NULL
Ets-1	NULL
(	NULL
28	NULL
)	NULL
or	NULL
Myb	NULL
(	NULL
4	NULL
)	NULL
transcription	NULL
factor	NULL
,	NULL
and	NULL
the	NULL
adjacent	NULL
Mono	NULL
A	NULL
site	NULL
includes	NULL
a	NULL
GGAA	NULL
core	NULL
characteristic	NULL
of	NULL
Ets	NULL
family-binding	NULL
sites	NULL
.	NULL

Whether	NULL
Mono	NULL
A	NULL
represents	NULL
a	NULL
member	NULL
of	NULL
the	NULL
Ets	NULL
family	NULL
(	NULL
which	NULL
includes	NULL
the	NULL
PU.1	NULL
factor	NULL
binding	NULL
downstream	NULL
of	NULL
region	NULL
II	NULL
)	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

We	NULL
found	NULL
no	NULL
direct	NULL
evidence	NULL
for	NULL
interaction	NULL
between	NULL
PU.1	NULL
and	NULL
the	NULL
upstream	NULL
factors	NULL
.	NULL

We	NULL
did	NULL
not	NULL
detect	NULL
PU.1-binding-site	NULL
complexes	NULL
that	NULL
migrate	NULL
more	NULL
slowly	NULL
than	NULL
in	NULL
vitro	NULL
translated	NULL
PU.1	NULL
,	NULL
suggesting	NULL
the	NULL
absence	NULL
of	NULL
formation	NULL
of	NULL
a	NULL
complex	NULL
-88	NULL
-59	NULL
-33	NULL
V	NULL
<	NULL
--	NULL
--	NULL
-	NULL
Region	NULL
II	NULL
--	NULL
--	NULL
--	NULL
>	NULL
V	NULL
Â«	NULL
â¬	NULL
--	NULL
--	NULL
-	NULL
PU.1	NULL
--	NULL
--	NULL
-	NULL
>	NULL
V	NULL
HUMAN	NULL
C	NULL
NAR	NULL
CTCTH	NULL
GCCTAGCTAAAAGGGGAAGAAGAGCGATC	NULL
t44+	NULL
tt++44+	NULL
+44	NULL
++4++4	NULL
t++4++4++4++4+4++	NULL
+44	NULL
CAATATTTCCAAATTCTGTAGTTCCCTTTCAGGCAAAAAAGGGGAAGAGGAG	NULL
MURINE	NULL
CCTAAAAAAAAAAAAAAAAAAAA	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

Conservation	NULL
of	NULL
sequence	NULL
similarity	NULL
of	NULL
the	NULL
human	NULL
and	NULL
murine	NULL
CSF-1	NULL
receptor	NULL
promoters	NULL
in	NULL
the	NULL
region	NULL
II-	NULL
and	NULL
PU.1-binding	NULL
domains	NULL
.	NULL

Shown	NULL
on	NULL
the	NULL
top	NULL
line	NULL
are	NULL
the	NULL
human	NULL
region	NULL
II	NULL
(	NULL
-88	NULL
to	NULL
-59	NULL
)	NULL
and	NULL
PU.1	NULL
site	NULL
(	NULL
the	NULL
purine	NULL
core	NULL
is	NULL
indicated	NULL
)	NULL
;	NULL
shown	NULL
on	NULL
the	NULL
bottom	NULL
line	NULL
is	NULL
the	NULL
murine	NULL
promoter	NULL
.	NULL

Identities	NULL
are	NULL
indicated	NULL
with	NULL
plus	NULL
signs	NULL
between	NULL
the	NULL
lines	NULL
.	NULL

The	NULL
murine	NULL
gene	NULL
contains	NULL
an	NULL
additional	NULL
23	NULL
bases	NULL
,	NULL
including	NULL
a	NULL
string	NULL
of	NULL
20	NULL
adenine	NULL
residues	NULL
,	NULL
between	NULL
region	NULL
II	NULL
and	NULL
the	NULL
PU.1	NULL
site	NULL
,	NULL
which	NULL
are	NULL
not	NULL
found	NULL
in	NULL
the	NULL
human	NULL
promoter	NULL
.	NULL

These	NULL
bases	NULL
are	NULL
shown	NULL
below	NULL
the	NULL
murine	NULL
sequence	NULL
to	NULL
preserve	NULL
the	NULL
alignment	NULL
.	NULL

The	NULL
bases	NULL
in	NULL
region	NULL
II	NULL
which	NULL
were	NULL
mutated	NULL
to	NULL
form	NULL
mutant	NULL
A	NULL
and	NULL
mutant	NULL
B	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
are	NULL
shaded	NULL
,	NULL
while	NULL
the	NULL
sequences	NULL
present	NULL
in	NULL
the	NULL
oligonucleotides	NULL
which	NULL
bind	NULL
separately	NULL
to	NULL
Mono	NULL
A	NULL
and	NULL
Mono	NULL
B	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
are	NULL
indicated	NULL
with	NULL
brackets	NULL
above	NULL
the	NULL
human	NULL
sequence	NULL
.	NULL

8094	NULL
ZHANG	NULL
ET	NULL
AL	NULL
.	NULL

between	NULL
PU.1	NULL
and	NULL
another	NULL
factor	NULL
.	NULL

Furthermore	NULL
,	NULL
PU.1	NULL
and	NULL
the	NULL
upstream	NULL
factors	NULL
bind	NULL
with	NULL
strong	NULL
affinity	NULL
to	NULL
oligonucleotides	NULL
that	NULL
contain	NULL
only	NULL
single	NULL
binding	NULL
sites	NULL
for	NULL
either	NULL
PU.1	NULL
or	NULL
the	NULL
two	NULL
upstream	NULL
factors	NULL
,	NULL
demonstrating	NULL
that	NULL
the	NULL
factors	NULL
can	NULL
bind	NULL
in	NULL
vitro	NULL
independently	NULL
of	NULL
each	NULL
other	NULL
.	NULL

Finally	NULL
,	NULL
mutations	NULL
in	NULL
the	NULL
PU.1	NULL
site	NULL
or	NULL
the	NULL
region	NULL
II	NULL
sites	NULL
each	NULL
decrease	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
activity	NULL
significantly	NULL
,	NULL
demonstrating	NULL
that	NULL
the	NULL
PU.1	NULL
factor	NULL
can	NULL
not	NULL
replace	NULL
the	NULL
Mono	NULL
A	NULL
or	NULL
Mono	NULL
B	NULL
complex	NULL
,	NULL
and	NULL
vice	NULL
versa	NULL
,	NULL
in	NULL
stimulating	NULL
full	NULL
promoter	NULL
activity	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
still	NULL
possible	NULL
that	NULL
PU.1	NULL
and	NULL
these	NULL
upstream	NULL
region	NULL
binding	NULL
factors	NULL
interact	NULL
,	NULL
either	NULL
through	NULL
alterations	NULL
in	NULL
chromatin	NULL
struc-ture	NULL
,	NULL
through	NULL
contacts	NULL
with	NULL
non-DNA-binding	NULL
coactivators	NULL
,	NULL
or	NULL
through	NULL
direct	NULL
protein-protein	NULL
contacts	NULL
that	NULL
are	NULL
not	NULL
stable	NULL
in	NULL
gel	NULL
shift	NULL
assays	NULL
.	NULL

To	NULL
find	NULL
common	NULL
themes	NULL
governing	NULL
myeloid	NULL
gene	NULL
regulation	NULL
,	NULL
it	NULL
is	NULL
interesting	NULL
to	NULL
consider	NULL
the	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
in	NULL
comparison	NULL
with	NULL
that	NULL
of	NULL
CD11b	NULL
,	NULL
a	NULL
myeloid	NULL
cell-specific	NULL
integrin	NULL
receptor	NULL
(	NULL
2	NULL
,	NULL
15	NULL
,	NULL
16	NULL
)	NULL
.	NULL

Both	NULL
lack	NULL
TATAA	NULL
boxes	NULL
and	NULL
have	NULL
a	NULL
functionally	NULL
important	NULL
PU.1	NULL
site	NULL
20	NULL
to	NULL
40	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
major	NULL
5	NULL
'	NULL
transcription	NULL
start	NULL
site	NULL
.	NULL

However	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
important	NULL
PU.1	NULL
site	NULL
is	NULL
unlikely	NULL
to	NULL
be	NULL
the	NULL
only	NULL
significant	NULL
factor	NULL
in	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
specificity	NULL
,	NULL
because	NULL
PU.1	NULL
itself	NULL
is	NULL
expressed	NULL
at	NULL
high	NULL
levels	NULL
in	NULL
both	NULL
macrophages	NULL
and	NULL
B	NULL
cells	NULL
(	NULL
6	NULL
)	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
,	NULL
the	NULL
promoter	NULL
has	NULL
a	NULL
second	NULL
functionally	NULL
important	NULL
binding	NULL
region	NULL
within	NULL
40	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
PU.1	NULL
site	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
two	NULL
factors	NULL
highly	NULL
expressed	NULL
in	NULL
monocytic	NULL
cells	NULL
.	NULL

These	NULL
factors	NULL
are	NULL
not	NULL
expressed	NULL
at	NULL
significant	NULL
levels	NULL
in	NULL
B	NULL
cells	NULL
,	NULL
perhaps	NULL
explaining	NULL
why	NULL
the	NULL
CSF-1	NULL
receptor	NULL
is	NULL
not	NULL
expressed	NULL
at	NULL
high	NULL
levels	NULL
in	NULL
B	NULL
cells	NULL
,	NULL
despite	NULL
the	NULL
presence	NULL
of	NULL
high	NULL
levels	NULL
of	NULL
PU.1	NULL
.	NULL

Our	NULL
mutational	NULL
analysis	NULL
of	NULL
the	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
,	NULL
in	NULL
which	NULL
mutations	NULL
of	NULL
either	NULL
the	NULL
Mono	NULL
A	NULL
or	NULL
the	NULL
Mono	NULL
B	NULL
site	NULL
reduce	NULL
promoter	NULL
activity	NULL
87	NULL
%	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
intact	NULL
PU.1	NULL
site	NULL
,	NULL
further	NULL
supports	NULL
the	NULL
idea	NULL
that	NULL
the	NULL
region	NULL
II-binding	NULL
factors	NULL
are	NULL
critical	NULL
for	NULL
macrophage	NULL
expression	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
.	NULL

To	NULL
examine	NULL
any	NULL
possible	NULL
functional	NULL
relationship	NULL
between	NULL
Mono	NULL
A	NULL
and	NULL
Mono	NULL
B	NULL
in	NULL
directing	NULL
CSF-1	NULL
receptor	NULL
promoter	NULL
activity	NULL
,	NULL
a	NULL
construct	NULL
which	NULL
deleted	NULL
both	NULL
the	NULL
Mono	NULL
A-and	NULL
the	NULL
Mono	NULL
B-binding	NULL
sites	NULL
simultaneously	NULL
was	NULL
used	NULL
in	NULL
transient	NULL
transfections	NULL
.	NULL

The	NULL
promoter	NULL
activity	NULL
of	NULL
the	NULL
double-deletion	NULL
construct	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
constructs	NULL
containing	NULL
either	NULL
the	NULL
Mono	NULL
A	NULL
or	NULL
Mono	NULL
B	NULL
site	NULL
mutation	NULL
individually	NULL
.	NULL

This	NULL
result	NULL
indicates	NULL
that	NULL
Mono	NULL
A	NULL
and	NULL
Mono	NULL
B	NULL
are	NULL
both	NULL
essential	NULL
for	NULL
monocyte-specific	NULL
expression	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
.	NULL

The	NULL
results	NULL
reported	NULL
here	NULL
support	NULL
the	NULL
original	NULL
observations	NULL
of	NULL
Roberts	NULL
et	NULL
al	NULL
.	NULL

(	NULL
18	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
a	NULL
550-bp	NULL
fragment	NULL
immediately	NULL
upstream	NULL
of	NULL
the	NULL
transcribed	NULL
region	NULL
of	NULL
the	NULL
human	NULL
CSF-1	NULL
receptor	NULL
gene	NULL
can	NULL
mediate	NULL
tissue-specific	NULL
expression	NULL
in	NULL
myelomonocytic	NULL
cells	NULL
.	NULL

Subsequent	NULL
studies	NULL
confirmed	NULL
these	NULL
results	NULL
and	NULL
demonstrated	NULL
monocyte-specific	NULL
transcriptional	NULL
activity	NULL
by	NULL
nuclear	NULL
run-on	NULL
analysis	NULL
(	NULL
30	NULL
)	NULL
.	NULL

An	NULL
entirely	NULL
different	NULL
model	NULL
was	NULL
recently	NULL
proposed	NULL
by	NULL
Yue	NULL
et	NULL
al	NULL
.	NULL

(	NULL
29	NULL
)	NULL
,	NULL
who	NULL
studied	NULL
a	NULL
similar	NULL
region	NULL
of	NULL
the	NULL
murine	NULL
CSF-1	NULL
receptor	NULL
gene	NULL
.	NULL

They	NULL
concluded	NULL
that	NULL
the	NULL
gene	NULL
contains	NULL
a	NULL
constitutively	NULL
active	NULL
promoter	NULL
and	NULL
that	NULL
the	NULL
macrophage-specific	NULL
production	NULL
of	NULL
full-length	NULL
mRNA	NULL
is	NULL
controlled	NULL
by	NULL
sequences	NULL
in	NULL
intron	NULL
2	NULL
that	NULL
regulate	NULL
transcript	NULL
elongation	NULL
.	NULL

Whether	NULL
this	NULL
discrepancy	NULL
reflects	NULL
inherent	NULL
differences	NULL
between	NULL
the	NULL
human	NULL
and	NULL
murine	NULL
promoters	NULL
is	NULL
not	NULL
clear	NULL
,	NULL
although	NULL
the	NULL
striking	NULL
conservation	NULL
between	NULL
the	NULL
two	NULL
promoters	NULL
in	NULL
the	NULL
region	NULL
II-	NULL
and	NULL
PU.1-binding	NULL
domains	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
suggests	NULL
that	NULL
they	NULL
could	NULL
direct	NULL
monocyte-specific	NULL
expression	NULL
of	NULL
both	NULL
the	NULL
murine	NULL
and	NULL
human	NULL
CSF-1	NULL
receptors	NULL
.	NULL

The	NULL
concept	NULL
of	NULL
the	NULL
CSF-1	NULL
promoter	NULL
itself	NULL
as	NULL
the	NULL
major	NULL
determinant	NULL
of	NULL
tissue	NULL
specificity	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
demonstration	NULL
that	NULL
the	NULL
upstream	NULL
fragment	NULL
identified	NULL
by	NULL
Roberts	NULL
et	NULL
al	NULL
.	NULL

(	NULL
18	NULL
)	NULL
directs	NULL
macrophage-specific	NULL
expression	NULL
of	NULL
the	NULL
receptor	NULL
in	NULL
transgenic	NULL
mice	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

Mono	NULL
A	NULL
and	NULL
Mono	NULL
B	NULL
protein	NULL
complexes	NULL
are	NULL
preferentially	NULL
detected	NULL
in	NULL
mobility	NULL
shift	NULL
assays	NULL
in	NULL
cells	NULL
of	NULL
the	NULL
monocyte	NULL
lineage	NULL
and	NULL
bind	NULL
to	NULL
sequence	NULL
elements	NULL
in	NULL
region	NULL
II	NULL
of	NULL
the	NULL
promoter	NULL
and	NULL
that	NULL
these	NULL
sequences	NULL
are	NULL
required	NULL
for	NULL
tissue-specific	NULL
expression	NULL
of	NULL
this	NULL
promoter	NULL
fragment	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
preponderance	NULL
of	NULL
data	NULL
support	NULL
the	NULL
conclusion	NULL
that	NULL
the	NULL
CSF-1	NULL
promoter	NULL
sequences	NULL
themselves	NULL
are	NULL
responsible	NULL
for	NULL
macrophage-specific	NULL
expression	NULL
of	NULL
the	NULL
CSF-1	NULL
receptor	NULL
and	NULL
certainly	NULL
argue	NULL
against	NULL
the	NULL
interpretation	NULL
that	NULL
the	NULL
CSF-1	NULL
promoter	NULL
is	NULL
constitutively	NULL
active	NULL
in	NULL
all	NULL
cell	NULL
types	NULL
.	NULL

Further	NULL
characterization	NULL
of	NULL
the	NULL
region	NULL
II-binding	NULL
proteins	NULL
should	NULL
aid	NULL
in	NULL
elucidating	NULL
the	NULL
mechanism	NULL
of	NULL
how	NULL
a	NULL
small	NULL
number	NULL
of	NULL
DNA-binding	NULL
proteins	NULL
within	NULL
a	NULL
small	NULL
promoter	NULL
region	NULL
can	NULL
mediate	NULL
macrophage-specific	NULL
expression	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
H.	NULL
W.	NULL
L.	NULL
Ziegler-Heitbrock	NULL
,	NULL
James	NULL
Griffin	NULL
,	NULL
Livingston	NULL
Van	NULL
De	NULL
Water	NULL
,	NULL
and	NULL
Cox	NULL
Terhorst	NULL
for	NULL
providing	NULL
Mono	NULL
Mac	NULL
6	NULL
,	NULL
REX	NULL
,	NULL
THP-1	NULL
,	NULL
and	NULL
Jurkat	NULL
and	NULL
BJA-B	NULL
cells	NULL
,	NULL
respectively	NULL
,	NULL
and	NULL
Scott	NULL
Hiebert	NULL
for	NULL
the	NULL
anti-AML1	NULL
antiserum	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
grants	NULL
CA41456	NULL
(	NULL
D.G.T	NULL
.	NULL
)	NULL

,	NULL
CA/AIS59589	NULL
(	NULL
D.-E.Z	NULL
.	NULL
)	NULL

,	NULL
and	NULL
RO1	NULL
CA42804	NULL
(	NULL
A.T.L	NULL
.	NULL
)	NULL

and	NULL
Cancer	NULL
Center	NULL
Support	NULL
(	NULL
CORE	NULL
)	NULL
grant	NULL
P30	NULL
CA21765	NULL
from	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
and	NULL
by	NULL
the	NULL
American	NULL
Lebanese	NULL
Syrian	NULL
Associated	NULL
Charities	NULL
,	NULL
St.	NULL
Jude	NULL
Children	NULL
's	NULL
Research	NULL
Hospital	NULL
.	NULL

D.G.T	NULL
.	NULL

is	NULL
a	NULL
Scholar	NULL
of	NULL
the	NULL
Leukemia	NULL
Society	NULL
of	NULL
America	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Brasier	NULL
,	NULL
A.	NULL
R.	NULL
,	NULL
J.	NULL
E.	NULL
Tate	NULL
,	NULL
and	NULL
J.	NULL
F.	NULL
Habener	NULL
.	NULL

1989	NULL
.	NULL

Optimized	NULL
use	NULL
of	NULL
the	NULL
firefly	NULL
luciferase	NULL
assay	NULL
as	NULL
a	NULL
reporter	NULL
gene	NULL
in	NULL
mammalian	NULL
cell	NULL
lines	NULL
.	NULL

BioTechniques	NULL
7:1116-1122	NULL
.	NULL

2	NULL
.	NULL

Chen	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
H.	NULL
L.	NULL
Pahl	NULL
,	NULL
R.	NULL
J.	NULL
Scheibe	NULL
,	NULL
D.	NULL
E.	NULL
Zhang	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
Spl	NULL
transcription	NULL
factor	NULL
binds	NULL
the	NULL
CD11b	NULL
promoter	NULL
specifically	NULL
in	NULL
myeloid	NULL
cells	NULL
in	NULL
vivo	NULL
and	NULL
is	NULL
essential	NULL
for	NULL
myeloid-specific	NULL
promoter	NULL
activity	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:8230-8239	NULL
.	NULL

3	NULL
.	NULL

Dignam	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
R.	NULL
M.	NULL
Lebovitz	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1983	NULL
.	NULL

Accurate	NULL
transcription	NULL
initiation	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
in	NULL
a	NULL
soluble	NULL
extract	NULL
from	NULL
isolated	NULL
mammalian	NULL
nuclei	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11:1475-1489	NULL
.	NULL

4	NULL
.	NULL

Hernandez-Munain	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
M.	NULL
S.	NULL
Krangel	NULL
.	NULL

1994	NULL
.	NULL

Regulation	NULL
of	NULL
the	NULL
T-cell	NULL
receptor	NULL
delta	NULL
enhancer	NULL
by	NULL
functional	NULL
cooperation	NULL
between	NULL
c-Myb	NULL
and	NULL
core-binding	NULL
factors	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:473-483	NULL
.	NULL

5	NULL
.	NULL

Kamachi	NULL
,	NULL
Y.	NULL
,	NULL
E.	NULL
Ogawa	NULL
,	NULL
M.	NULL
Asano	NULL
,	NULL
S.	NULL
Ishida	NULL
,	NULL
Y.	NULL
Murakami	NULL
,	NULL
M.	NULL
Satake	NULL
,	NULL
Y.	NULL
Ito	NULL
,	NULL
and	NULL
K.	NULL
Shigesada	NULL
.	NULL

1990	NULL
.	NULL

Purification	NULL
of	NULL
a	NULL
mouse	NULL
nuclear	NULL
factor	NULL
that	NULL
binds	NULL
to	NULL
both	NULL
the	NULL
A	NULL
and	NULL
B	NULL
cores	NULL
of	NULL
the	NULL
polyomavirus	NULL
enhancer	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:4808-4819	NULL
.	NULL

6	NULL
.	NULL

Klemsz	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
S.	NULL
R.	NULL
McKercher	NULL
,	NULL
A.	NULL
Celada	NULL
,	NULL
C.	NULL
Van	NULL
Beveren	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Maki	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
macrophage	NULL
and	NULL
B	NULL
cell-specific	NULL
transcription	NULL
factor	NULL
PU.1	NULL
is	NULL
related	NULL
to	NULL
the	NULL
ets	NULL
oncogene	NULL
.	NULL

Cell	NULL
61:113-124	NULL
.	NULL

7	NULL
.	NULL

Meyers	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
R.	NULL
Downing	NULL
,	NULL
and	NULL
S.	NULL
W.	NULL
Hiebert	NULL
.	NULL

1993	NULL
.	NULL

Identification	NULL
of	NULL
AML-1	NULL
and	NULL
the	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
translocation	NULL
protein	NULL
(	NULL
AML-1/ETO	NULL
)	NULL
as	NULL
sequence-specific	NULL
DNA-binding	NULL
proteins	NULL
:	NULL
the	NULL
runt	NULL
homology	NULL
domain	NULL
is	NULL
required	NULL
for	NULL
DNA	NULL
binding	NULL
and	NULL
protein-protein	NULL
interactions	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

13:6336-6345	NULL
.	NULL

8	NULL
.	NULL

Miyazaki	NULL
,	NULL
T.	NULL
,	NULL
G.	NULL
Suzuki	NULL
,	NULL
and	NULL
K.-L.	NULL
Yamamura	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
role	NULL
of	NULL
macrophages	NULL
in	NULL
antigen	NULL
presentation	NULL
and	NULL
T	NULL
cell	NULL
tolerance	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

5:1023-1033	NULL
.	NULL

9	NULL
.	NULL

Miyoshi	NULL
,	NULL
H.	NULL
,	NULL
K.	NULL
Shimizu	NULL
,	NULL
T.	NULL
Kozu	NULL
,	NULL
N.	NULL
Maseki	NULL
,	NULL
Y.	NULL
Kaneko	NULL
,	NULL
and	NULL
M.	NULL
Ohki	NULL
.	NULL

1991.	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
breakpoints	NULL
on	NULL
chromosome	NULL
21	NULL
in	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
are	NULL
clustered	NULL
within	NULL
a	NULL
limited	NULL
region	NULL
of	NULL
a	NULL
single	NULL
gene	NULL
,	NULL
AML1	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:10431-10434	NULL
.	NULL

10	NULL
.	NULL

Nordeen	NULL
,	NULL
S.	NULL
K.	NULL
1988	NULL
.	NULL

Luciferase	NULL
reporter	NULL
gene	NULL
vectors	NULL
for	NULL
analysis	NULL
of	NULL
promoters	NULL
and	NULL
enhancers	NULL
.	NULL

BioTechniques	NULL
6:454-458	NULL
.	NULL

11	NULL
.	NULL

Nuchprayoon	NULL
,	NULL
I.	NULL
,	NULL
S.	NULL
Meyers	NULL
,	NULL
L.	NULL
M.	NULL
Scott	NULL
,	NULL
J.	NULL
Suzow	NULL
,	NULL
S.	NULL
Hiebert	NULL
,	NULL
and	NULL
A.	NULL
D.	NULL
Friedman	NULL
.	NULL

1994	NULL
.	NULL

PEBP2/CBF	NULL
,	NULL
the	NULL
murine	NULL
homolog	NULL
of	NULL
the	NULL
human	NULL
myeloid	NULL
AML1	NULL
and	NULL
PEBP2B/CBFRB	NULL
proto-oncoproteins	NULL
,	NULL
regulates	NULL
the	NULL
murine	NULL
myeloperoxidase	NULL
and	NULL
neutrophil	NULL
elastase	NULL
genes	NULL
in	NULL
immature	NULL
myeloid	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:5558-5568	NULL
.	NULL

12	NULL
.	NULL

Ogawa	NULL
,	NULL
M.	NULL
1993	NULL
.	NULL

Differentiation	NULL
and	NULL
proliferation	NULL
of	NULL
hematopoietic	NULL
stem	NULL
cells	NULL
.	NULL

Blood	NULL
81:2844-2853	NULL
.	NULL

Vor	NULL
.	NULL

14	NULL
,	NULL
1994	NULL
13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

Owen	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
D.	NULL
M.	NULL
Bortner	NULL
,	NULL
and	NULL
M.	NULL
C.	NULL
Ostrowski	NULL
.	NULL

1990.	NULL
ras	NULL
oncogene	NULL
activation	NULL
of	NULL
a	NULL
VL3O0	NULL
transcriptional	NULL
element	NULL
is	NULL
linked	NULL
to	NULL
transformation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:1-9	NULL
.	NULL

Pahl	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
T.	NULL
C.	NULL
Burn	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

1991	NULL
.	NULL

Optimization	NULL
of	NULL
transient	NULL
transfection	NULL
into	NULL
human	NULL
myeloid	NULL
cell	NULL
lines	NULL
using	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
.	NULL

Exp	NULL
.	NULL

Hematol	NULL
.	NULL

19:1038-1041	NULL
.	NULL

Pahl	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
A.	NULL
G.	NULL
Rosmarin	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

1992	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
myeloid-specific	NULL
CD11b	NULL
promoter	NULL
.	NULL

Blood	NULL
79:865-870	NULL
.	NULL

Pahl	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
R.	NULL
J.	NULL
Scheibe	NULL
,	NULL
D.	NULL
E.	NULL
Zhang	NULL
,	NULL
H.	NULL
M.	NULL
Chen	NULL
,	NULL
D.	NULL
L.	NULL
Galson	NULL
,	NULL
R.	NULL
A.	NULL
Maki	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
proto-oncogene	NULL
PU.1	NULL
regulates	NULL
expression	NULL
of	NULL
the	NULL
myeloid-specific	NULL
CD11b	NULL
promoter	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:5014-5020	NULL
.	NULL

Pevny	NULL
,	NULL
L.	NULL
,	NULL
M.	NULL
C.	NULL
Simon	NULL
,	NULL
E.	NULL
Robertson	NULL
,	NULL
W.	NULL
H.	NULL
Klein	NULL
,	NULL
S.	NULL
F.	NULL
Tsai	NULL
,	NULL
V.	NULL
D'Agati	NULL
,	NULL
S.	NULL
H.	NULL
Orkin	NULL
,	NULL
and	NULL
F.	NULL
Costantini	NULL
.	NULL

1991	NULL
.	NULL

Erythroid	NULL
differentiation	NULL
in	NULL
chimaeric	NULL
mice	NULL
blocked	NULL
by	NULL
a	NULL
targeted	NULL
mutation	NULL
in	NULL
the	NULL
gene	NULL
for	NULL
transcription	NULL
factor	NULL
GATA-1	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
349:257-260	NULL
.	NULL

Roberts	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
L.	NULL
H.	NULL
Shapiro	NULL
,	NULL
R.	NULL
A.	NULL
Ashmun	NULL
,	NULL
and	NULL
A.	NULL
T.	NULL
Look	NULL
.	NULL

1992	NULL
.	NULL

Transcription	NULL
of	NULL
the	NULL
human	NULL
colony-stimulating	NULL
factor-1	NULL
receptor	NULL
gene	NULL
is	NULL
regulated	NULL
by	NULL
separate	NULL
tissue-specific	NULL
promoters	NULL
.	NULL

Blood	NULL
79:586-593	NULL
.	NULL

Sariban	NULL
,	NULL
E.	NULL
,	NULL
T.	NULL
Mitchell	NULL
,	NULL
and	NULL
D.	NULL
Kufe	NULL
.	NULL

1985	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
c-fms	NULL
proto-oncogene	NULL
during	NULL
human	NULL
monocytic	NULL
differentiation	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
316:64-66	NULL
.	NULL

Sherr	NULL
,	NULL
C.	NULL
J	NULL
.	NULL

1990	NULL
.	NULL

Colony-stimulating	NULL
factor-1	NULL
receptor	NULL
.	NULL

Blood	NULL
75:1-12	NULL
.	NULL

Speck	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

Six	NULL
distinct	NULL
nuclear	NULL
factors	NULL
interact	NULL
with	NULL
the	NULL
75-base-pair	NULL
repeat	NULL
of	NULL
the	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
virus	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7:1101-1110	NULL
.	NULL

Stanley	NULL
,	NULL
E.	NULL
R.	NULL
,	NULL
L.	NULL
J.	NULL
Guilbert	NULL
,	NULL
R.	NULL
J.	NULL
Tushinski	NULL
,	NULL
and	NULL
S.	NULL
H.	NULL
Bartelmez	NULL
.	NULL

1983	NULL
.	NULL

CSF-1-a	NULL
mononuclear	NULL
phagocyte	NULL
lineage-specific	NULL
hemopoi-etic	NULL
growth	NULL
factor	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biochem	NULL
.	NULL

21:151-159	NULL
.	NULL

Thornell	NULL
,	NULL
A.	NULL
,	NULL
B.	NULL
Hallberg	NULL
,	NULL
and	NULL
T.	NULL
Grundstrom	NULL
.	NULL

1988	NULL
.	NULL

Differential	NULL
protein	NULL
binding	NULL
in	NULL
lymphocytes	NULL
to	NULL
a	NULL
sequence	NULL
in	NULL
the	NULL
enhancer	NULL
of	NULL
CSF-1	NULL
RECEPTOR	NULL
MONOCYTIC	NULL
REGULATORY	NULL
ELEMENT	NULL
24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

8095	NULL
the	NULL
mouse	NULL
retrovirus	NULL
SL3-3	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8:1625-1637	NULL
.	NULL

Visvader	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
I.	NULL
M.	NULL
Verma	NULL
.	NULL

1989	NULL
.	NULL

Differential	NULL
transcription	NULL
of	NULL
exon	NULL
1	NULL
of	NULL
the	NULL
human	NULL
c-fms	NULL
gene	NULL
in	NULL
placental	NULL
trophoblasts	NULL
and	NULL
monocytes	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

9:1336-1341	NULL
.	NULL

Voso	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
T.	NULL
C.	NULL
Burn	NULL
,	NULL
G.	NULL
Wulf	NULL
,	NULL
B.	NULL
Lim	NULL
,	NULL
G.	NULL
Leone	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

1994	NULL
.	NULL

Inhibition	NULL
of	NULL
hematopoiesis	NULL
by	NULL
competitive	NULL
binding	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
PU.1	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:7932-7936	NULL
.	NULL

Wang	NULL
,	NULL
S.	NULL
,	NULL
Q.	NULL
Wang	NULL
,	NULL
B.	NULL
E.	NULL
Crute	NULL
,	NULL
I.	NULL
N.	NULL
Melnikova	NULL
,	NULL
S.	NULL
R.	NULL
Keller	NULL
,	NULL
and	NULL
N.	NULL
A.	NULL
Speck	NULL
.	NULL

1993	NULL
.	NULL

Cloning	NULL
and	NULL
characterization	NULL
of	NULL
subunits	NULL
of	NULL
the	NULL
T-cell	NULL
receptor	NULL
and	NULL
murine	NULL
leukemia	NULL
virus	NULL
enhancer	NULL
core-binding	NULL
factor	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:3324-3339	NULL
.	NULL

Wang	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
and	NULL
N.	NULL
A.	NULL
Speck	NULL
.	NULL

1992	NULL
.	NULL

Purification	NULL
of	NULL
core-binding	NULL
factor	NULL
,	NULL
a	NULL
protein	NULL
that	NULL
binds	NULL
the	NULL
conserved	NULL
core	NULL
site	NULL
in	NULL
murine	NULL
leukemia	NULL
virus	NULL
enhancers	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:89-102	NULL
.	NULL

Wotton	NULL
,	NULL
D.	NULL
,	NULL
J.	NULL
Ghysdael	NULL
,	NULL
S.	NULL
Wang	NULL
,	NULL
N.	NULL
A.	NULL
Speck	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Owen	NULL
.	NULL

1994	NULL
.	NULL

Cooperative	NULL
binding	NULL
of	NULL
Ets-1	NULL
and	NULL
core	NULL
binding	NULL
factor	NULL
to	NULL
DNA	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

14:840-850	NULL
.	NULL

Yue	NULL
,	NULL
X.	NULL
,	NULL
P.	NULL
Favot	NULL
,	NULL
T.	NULL
L.	NULL
Dunn	NULL
,	NULL
A.	NULL
I.	NULL
Cassady	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Hume	NULL
.	NULL

1993	NULL
.	NULL

Expression	NULL
of	NULL
mRNA	NULL
encoding	NULL
the	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
receptor	NULL
(	NULL
c-fms	NULL
)	NULL
is	NULL
controlled	NULL
by	NULL
a	NULL
constitutive	NULL
promoter	NULL
and	NULL
tissue-specific	NULL
transcription	NULL
elongation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13	NULL
:	NULL
3191-3201	NULL
.	NULL

Zhang	NULL
,	NULL
D.-E.	NULL
,	NULL
C.	NULL
J.	NULL
Hetherington	NULL
,	NULL
H.-M.	NULL
Chen	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
macrophage	NULL
transcription	NULL
factor	NULL
PU.1	NULL
directs	NULL
tissue-specific	NULL
expression	NULL
of	NULL
the	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
receptor	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:373-381	NULL
.	NULL

Zhang	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
P.	NULL
R.	NULL
Hoyt	NULL
,	NULL
and	NULL
J.	NULL
Papaconstantinou	NULL
.	NULL

1990	NULL
.	NULL

Localization	NULL
of	NULL
DNA	NULL
protein-binding	NULL
sites	NULL
in	NULL
the	NULL
proximal	NULL
and	NULL
distal	NULL
promoter	NULL
regions	NULL
of	NULL
the	NULL
mouse	NULL
alpha-fetoprotein	NULL
gene	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265:3382-3391	NULL
.	NULL

Ziegler-Heitbrock	NULL
,	NULL
H.	NULL
W.	NULL
,	NULL
E.	NULL
Thiel	NULL
,	NULL
A.	NULL
Futterer	NULL
,	NULL
V.	NULL
Herzog	NULL
,	NULL
A.	NULL
Wirtz	NULL
,	NULL
and	NULL
G.	NULL
Riethmuller	NULL
.	NULL

1988	NULL
.	NULL

Establishment	NULL
of	NULL
a	NULL
human	NULL
cell	NULL
line	NULL
(	NULL
Mono	NULL
Mac	NULL
6	NULL
)	NULL
with	NULL
characteristics	NULL
of	NULL
mature	NULL
monocytes	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
41:456-461	NULL
.	NULL

